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ABSTRACT 
 
According to the Demographic and Health Survey in Zambia the national HIV prevalence 
among population aged 15-49 years was 14%. In 2002 the Government of Zambia 
introduced Antiretroviral Therapy (ART) in two of the largest hospitals in Zambia: 
Lusaka and Ndola hospitals. As many people begin accessing ART in rural areas in 
Zambia, one of the major challenges is ensuring that those receiving ART adhere to 
treatment to avoid the emergence of drug resistance and treatment failure. The research 
therefore set to identify the potential barriers and facilitators to antiretroviral treatment 
adherence among people living with HIV and AIDS in the rural district of Chongwe, 
Zambia.   
 
A descriptive qualitative study was conducted over a period of three weeks from 11th 
December to 29th December 2008. The perceptions, opinions and experiences of PLHIV 
on ART and those of the health workers and treatment supporters were explored through 
in-depth interviews and focus group discussions.  In-depth interviews were conducted 
with nine persons living with HIV (PLHIV): 5 females and 4 males.  Two focus group 
discussions were conducted with members of 2 different PLHIV support groups from 
Refunsa and Chimusanya villages served by the ART clinic of St Luke Mission Hospital 
and another with a group of ART treatment supporters. In addition, interviews were held 
with five key informants, who were health workers from the ART clinic in St Luke 
Mission Hospital in Mpanshaya.   
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Reported barriers to adherence among PLHIV in rural areas included experiencing side 
effects to ART drugs, stopping medication due to improvement in wellbeing, a lack of 
understanding of the importance of adherence, and forgetting to take their medication due 
to alcohol consumption. Other barriers included stigma and discrimination, inadequate 
food to support ART uptake and non disclosure of one’s status for fear of being rejected 
especially for women who feared rejection in relationships. Another key barrier to 
adherence was the religious belief held by some PLHIV that one would get healed after 
being prayed for and therefore discontinued treatment. 
 
Key facilitators to adherence identified in the study included getting into a regular routine 
of taking antiretroviral drugs (ARVs), knowledge of and belief in the efficacy of ART, 
disclosure of HIV status, access to social support and nutritional support. Other 
facilitators identified were use of treatment supporters who provided support to PLHIV 
by providing them with on-going adherence counseling, and making referrals to the ART 
facility for further support, mobile ART clinics that have brought ART services closer to 
the rural communities and the adaptation of strategies such as clocks and use of alarms by 
PLHIV to remind them to take their medication. Although better health resulting from 
taking ARVs was citied as a barrier to adherence it also acted as a facilitator to adherence 
as better health motivated PLHIV to continue taking their medication. 
 
In conclusion, based on the findings from the study a series of recommendations were 
made to inform the current ART adherence information and counseling strategies used by 
the ART facility at St Luke Mission Hospital in Mpanshaya - and other ART programmes 
 
 
 
 
 v 
being implemented in similar rural health facilities in Zambia. The recommendations 
included the need for the ART facility to address alcohol abuse among PLHIV taking 
ART, addressing perceptions on ARVs in the community, reviewing of the counseling 
programme, caring for treatment supporters, strengthening food security and livelihood 
opportunities for PLHIV and their families and increasing collaboration between the 
ART facility and the churches. 
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 1 
CHAPTER ONE 
A DESCRIPTION OF THE STUDY 
 
1. Introduction  
HIV and AIDS continues to be a serious pandemic worldwide. As of 2007, the?estimated?
number of persons living with HIV (PLHIV) in the world was 33.2 million and Southern 
Africa remains the most affected region with just under a third (22.5 million) of PLHIV 
(UNAIDS, 2006).  With a population of over 10 million, the Zambian National AIDS 
Council (NAC) states that Zambia is one of the countries worst affected by HIV and 
AIDS in Sub Saharan Africa (NAC, 2006). A Demographic and Health Survey conducted 
in the country in 2007 (Central Statistics Office, 2007) put the national HIV prevalence 
rate among 15-49 year olds at 14%.  
 
The HIV prevalence in Lusaka is currently 18% and is, one of the highest in Zambia 
(CSO, 2007). This is above the national HIV prevalence rate for ages 14 to 49 year (CSO, 
2007). The Zambia Demographic Health Survey (CSO, 2007) also shows that HIV 
infection rates are higher among women than men between the ages of 35-39 years, at  
16% and 14% respectively. HIV and AIDS had adverse effect on the social and economic 
development of Zambia (NAC, 2006). The Joint United Nations Programme on HIV and 
AIDS (UNAIDS, 2007) states that about 1.1 million Zambians are living with HIV and 
AIDS, 57% of which are women. Of the people infected with HIV, only 27% were on 
antiretroviral therapy (ART) and many of these are food insecure without any nutritional 
support (NAC, 2004). ?
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It has long been recognized that there is a complex web of issues that are contributing to 
increased prevalence of HIV and AIDS – many of which are found in Zambia. These 
include poverty, socio-economic disparities, multiple concurrent partnerships, 
intergenerational sex, transactional sex, combined with low and inconsistent use of 
condoms, and gender based violence (UNAIDS, 2008). The level of poverty in many 
rural areas in Zambia has deepened given that the HIV epidemic has affected the most 
economically productive age group (NAC, 2004). In general, the high poverty level is 
one of the major factors influencing HIV transmission in Zambia as it directly or 
indirectly creates vulnerability to HIV and AIDS in Zambia (NAC, 2005). 
 
In some of the communities, socio-cultural practices like widow inheritance, sexual 
cleansing (a practice where a surviving spouse is required to have sex with a relation of 
the deceased), dry sex, which results in bruising and lacerations in the vagina among 
others; have increased the vulnerability of women to HIV transmission.  In addition, 
gender inequality and the resultant imbalance of power in sexual relationships has 
increased the vulnerability of women to HIV because they are unable to negotiate 
condom use or lack the necessary skills to be self-assertive in sexual relations (NAC, 
2004). 
 
1.1. Universal Access to Antiretroviral treatment 
In 2002, given the high rates of HIV infection, and following the World Health 
Organisation (WHO) and UNAIDS’ initiative to provide antiretroviral treatment (ART) 
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to three million people with HIV and AIDS in developing countries by 2005 (commonly 
referred to as the “3 by 5” initiative), the Zambian government decided to make 
antiretroviral therapy widely available to everyone in need of treatment. Consequently, 
three million United States dollars was allocated in 2004 for the purchase of antiretroviral 
drugs for 10 000 people, to be provided through public health services in Zambia (NAC, 
2004). Treatment in the public sector was initially delivered at a subsidized rate.   In the 
same year, 2004, the government introduced Antiretroviral Therapy (ART) in two of the 
largest hospitals in Zambia: the University Teaching Hospital (UTH) in Lusaka and the 
Ndola Central Hospital in Ndola city.  In 2004, the government announced that 
antiretroviral therapy would be provided free of charge in public hospitals at both 
districts and provincial levels. A comprehensive implementation plan to roll out access to 
treatment across the country has since been developed (NAC, 2004).  
 
By August 2005, treatment and laboratory costs at public institutions also became free. 
This facilitated increased treatment access for more people living with HIV. As a result 
by end of 2005 more than 50,000 out of the estimated 200,000 PLHIV in Zambia were on 
ART (NAC, 2006).   
 
ART can now be accessed in many primary care clinics and hospitals throughout the 
country including those in Chongwe district where this study took place.  Since 2005, 
substantial progress has been made in Zambia towards ensuring that those needing 
treatment, access it. As of 2007, UNAIDS & WHO (2008) estimated that in Zambia 54% 
PLHIV received treatment out of the 330,000 needing it.  
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An increase in ART availability and access to them notwithstanding, it is suggested that 
one of the factors contributing to the success of the ART programme in Zambia is for 
PLHIV to maintain consistent adherence to their ART regimes. High levels (at least 95%) 
of adherence to ART are needed to ensure optimal benefits (WHO, 2006). Poor drug 
adherence leads to treatment failure and accelerated sickness, which in turn creates the 
potential for drug resistance (WHO, 2003).  
 
In order to provide those on ART with the necessary support to achieve and sustain this 
level of adherence the government of Zambia, through the National AIDS Council, put in 
place a National Strategic Framework (NAC, 2004) outlining national priorities and 
programmes in prevention, treatment, care and support.  Additionally, NAC put in place 
national guidelines on the management and care of HIV, including guidelines on 
provision of ART, home based care (HBC), counseling and peer and social support to 
improve the quality of life for PLHIV (NAC, 2004). 
 
1.2. Problem statement 
In Zambia some research has been conducted on individual and community perceptions, 
knowledge, attitudes and experiences of HIV and AIDS and related treatment, treatment 
adherence, and HIV related stigma and discrimination (International HIV/AIDS Alliance, 
2003). However, little of this research has focused on the facilitators and barriers that are 
experienced by PLHIV taking ART and living in rural settings in Zambia. Establishing 
whether there are unique facilitating factors and barriers to ART adherence in rural areas 
in Zambia – which are different from those experienced by PLHIV on ART in urban 
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areas, could enable ART programme managers and health workers to put in place, if 
required, specific strategies to encourage and support drug adherence in more rural 
settings in the country. This in turn, would serve to support the scaling up of 
antiretroviral treatment programs in rural areas in Zambia. 
 
1.3. The Study context 
The research study was conducted at St Luke’s Mission Hospital in the rural town of 
Mpanshya, which is located within Chongwe District in Lusaka province.  Besides 
Mpanshaya village, two other villages, Rufunsa and Chimusanya – both approximately X 
kms from Mpanshaya village, were sampled for the study. Mpanshya is approximately 
200 km from Lusaka, the capital city of Zambia.  St Luke’s Mission is the only hospital 
in Chongwe district and provides a service to a rural population of almost 190, 000 
people. In addition, seven rural health centers from the surrounding villages refer cases to 
St Luke’s Mission Hospital. It is officially a District Hospital and the Chongwe District 
Health Management Team provides partial funding for the hospital and its staff.1  A 
Hospice, attached to the hospital, is responsible for the ART programme. The ART 
programme has been in place since 2005. At the time of the study, in September 2008, 
731 PLHIV were on ART (ART facility hospital records).  
 
While staff that deliver treatment at the ART facility at St Luke Mission hospital suggest 
that the quality of life of people on ART has improved overall, they acknowledge that 
                                                 
1 The hospital is run and managed by the Borromeo Sisters and has a Hospital Manager, one doctor, a 
Voluntary Services Overseas (VSO) volunteer, a Clinic officer, one sister in charge and six nurses. The 
hospice is staffed by a VSO volunteer nurse, 5 counselors and in addition the hospice is supported by 80 
community caregivers who also have been trained as ART treatment supporters. 
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PLHIV are facing challenges around ART adherence. To date, however, these challenges 
have not been documented in any rigorous form and have consequently not influenced 
the content and process of the consultation sessions the ART staff have with their HIV 
positive patients. Understanding the barriers and facilitators to adherence in this rural 
context would therefore contribute to improving the practice within the ART programme, 
and in providing a continuum of care for PLHIV and AIDS (Personal communication 
between VSO staff and St Lukes Mission Hospital ART staff, 31st May 2007).  
 
1.4. Structure of the mini-thesis 
The rest of the report has been divided into the following: 
• Chapter two mainly focuses on the literature review highlighting barriers and 
facilitators to adherence in developed and developing countries;  
• Chapter three focuses on the methodology used in the study; 
• Chapter four focuses on the presentation of the results; 
• Chapter five presents an analysis and discussion of the findings and 
• Chapter six is the conclusion, limitations of the study and highlights 
recommendations arising out of the study. 
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CHAPTER TWO 
LITERATURE REVIEW 
 
2. Introduction 
The literature review provides an overview of facilitators and barriers to ART adherence 
issues amongst people living with HIV. It further provides examples of research 
conducted in both developed and less developed countries to review the) that influence 
adherence amongst PLHIV living in rural settings similar to Zambia.  
 
As a result of provision of ART in many countries, including Africa, there has been a 
dramatic reduction in HIV-related morbidity and mortality (Attawell & Mundy, 2003). 
However, it is commonly recognized that many patients experience difficulty in 
following treatment recommendations generally (not only related to HIV) worldwide.  
For example, WHO has noted that adherence to long-term therapy for chronic illness 
including HIV and AIDS, in developed countries averages 50% and the rates in 
developing countries are much lower (WHO, 2003).  
 
Research shows that poor adherence to antiretroviral drugs will have an effect on the 
effectiveness of treatment and this increases the likelihood of drug resistance (WHO, 
2003). Non-adherence could also lead to treatment failure, disease progression and death 
(WHO, 2003; Stringer et al. 2006). Several authors state that very high level of adherence 
(greater than 95%) are required for antiretroviral therapy (ART) to be effective and to 
prevent the emergence of resistant viral strains (Paterson et al. 2000; Lckovics et al. 
2002). Given that developing countries have limited access to ART, ensuring early 
 
 
 
 
 8 
adherence is important as treatment options for HIV become limited once resistance 
develops (Chesney, 2003).   
 
2.1. Barriers and facilitators identified as affecting adherence in 
developed countries 
 In developed countries several studies have been conducted to ascertain what kinds of 
factors contribute to adherence or non-adherence among people living with HIV and 
AIDS. The following are the barriers to adherence in developing countries:  
 
2.1.1. Inadequate knowledge and patient belief systems 
Several studies (Robert, 2000; Chesney, 2003; Murphy et al.2000 and Sidat; Fairley & 
Gierson.2007) have noted that patients who have inadequate knowledge and 
understanding of the relationship between adherence, viral load and disease progression 
were more likely not to adhere to medication. For example, in a qualitative study on 
experiences and perceptions of patients with 100% adherence to Highly Active 
Antiretroviral Therapy, conducted in Australia, Sidat et al. (2007), argue that decreased 
adherence to ART has been found to be a result of patients’ disbelief, non acceptance of 
the disease and perceived lack of benefit of the treatment. 
 
2.1.2. Regime complexity as a barrier to adherence 
Studies conducted in the USA (Murphy et al. 2000; Roberts, 2002; Chesney, 2000 and 
Chesney, 2003) cite that regimen complexity which included taking multiple daily doses, 
sometimes with food restrictions greatly impacted on the PLHIV’s willingness to adhere 
to medication.  In addition, PLHIV that faced challenges such as following special drug 
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regime instructions, sleeping through the dose time and changes in the daily routines 
were more likely not to adhere to their medication.                
 
2.1.3. Side effects as a barrier to adherence 
The issue of side effects has been noted to have an effect on patient’s ability to continue 
taking prescribed medication (Roberts, 2002; Murphy et al.2000; Ammassari et al. 2001; 
Chesney, 2000; Ichovics and Meade 2002). For example, Ammassari et al. (2001), in 
their cross sectional multicenter study conducted in Italy found that patient-reported 
symptoms and medication side effects such as anxiety, fatigue, abnormal fat 
accumulation, diarrhea, nausea, anorexia and insomnia were reported among people who 
were not adherent to ART medication.  
 
Although several authors (Chesney, 2000; Ichovics and Meade 2002) have also cited side 
affects and symptoms, and suggest that patient’s views about medications may be 
complex and vary according to the type of regimen. The authors state that increased 
understanding of side effects and how to manage these assisted people on ART to 
continue taking their treatment and not get discouraged when they were experiencing 
intense side effects (Chesney, 2000; Chesney, 2003; Ichovics and Meade 2002). 
 
2.1.4. Drug abuse, alcohol abuse and psychological factors 
In addition, certain patient-related factors such as active drug and alcohol abuse and 
psychological factors such as anxiety and depression have been identified as critical 
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factors that can contribute to non-adherence to ART as this influences PLHIV’s ability to 
take their medication (Chesney, 2000; Power et al. 2003; Methta et al. 1997). 
 
2.1.5. A non supportive patient - provider relationship 
A non-supportive patient – provider relationship has been known to be a barrier for 
PLHIV to adhere (Murphy et al. 2000; Chesney, 2002; Chesney, 2003). Where PLHIV 
were unhappy with the quality of the health care provider relationship that included 
patient’s lack of satisfaction with their provider and quality of communication with the 
provider, this has contributed to lack of adherence. Chesney (2003) noted that treatment 
becomes complex, side effects go unmanaged and patients are less likely to adhere as 
they cope alone with such difficulties when the patients become frustrated as a result of 
miscommunication. 
 
Laws et al. (2000) in their study conducted in Massachusetts, USA on how people with 
HIV understand and experience the problem of adhering to antiretroviral medication 
regimes found that most patients were unable to recognize non-adherent behaviour and 
did not understand the consequences of missing doses. However, it was also noted that 
patients in the study did not discuss the issue of non-adherence with their physicians. Of 
the 25 respondents interviewed, 84% of the patients reported non-adherent behaviour, 
which included ceasing treatment, having medication ‘holidays’, sleeping through doses 
and skipping doses due to side effects (Laws et al. 2000). 
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2.1.6. Lack of social support  
While social support may be different, the quality of the social support from a partner, 
friend and family members can influence adherence to treatment. Lack of satisfaction 
with social support has been known to result in non-adherence to medication among 
people taking ARVs.  Perceived support from family members or a partner has been 
associated with adherence to HIV treatment as people were more comfortable and did not 
feel threatened to take the prescribed medication at the required time (Power et al. 2003; 
Turner, 2002). 
 
 
 
2.2. Facilitators to adherence among PLHIV in developed countries 
 
The following are the facilitators to adherence among PLHIV in developed countries. 
 
2.2.1. Belief in the efficacy and knowledge of medication  
Sidat et al. (2007) cite a combination of factors as contributing to achieving 100% ART 
adherence. These include PLHIV knowledge of ART and readiness or willingness to take 
it. For patients in the Australian study who consider taking medication as a life style and 
see ART as a lifeline responsible for improvements in their life, this reinforced their 
commitment to continue adhering to their treatment as it prolonged life and improved 
their quality of life. Therefore, patients who believed that taking treatment would prolong 
their lives were more likely to adhere to ART. Decreased adherence to ART has been 
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found to be a result of patients’ disbelief, non-acceptance of the disease and perceived 
lack of benefit of the treatment (Sidat et al. 2007).  
 
2.2.2. Supportive clinic-patient relationship as a facilitator to adherence 
The nature of the clinic-patient relationship can also contribute to adherence. Research 
findings in several literature sources (Chesney, 2000; Chesney, 2003 and Sidat et al. 
2007) highlight the importance of clinic-patient relationship that included patients feeling 
supported by their health care provider to take ART. Chesney (2003) and Sidat et al. 
(2007) suggest that patients that feel supported by their health provider are better able to 
continue taking their treatment. 
 
2.3. Barriers and facilitators identified as affecting adherence in 
developing countries 
There are obvious similarities in terms of the barriers and facilitators to ART adherence 
that operate in both the developed and developing world. These include side effects 
(Ammassari et al. 2001; Chesney 2000; Ichovics and Meade 2002; Dahab et al. 2008) 
which develop as a result of taking medication, patient and client relations (Chesney 
2000; Sidat et al. 2007), and alcohol abuse (Chesney, 2000; Power et al. 2003; Methta et 
al. 1997; Dahab et al. 2008; Weiser et al. 2003) which results in PLHIV not taking their 
medication consistently and therefore not adhering to medication.   
 
2.3.1. Socio-economic circumstances and cost of ART 
However, studies related to ART adherence conducted in developing countries indicate 
that there are slightly different and/or additional reasons that account for non-adherence 
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or adherence in these settings. Most of these can be attributed to differences in socio-
economic conditions and the accessibility of treatment.  
 
In some developing countries such as Botswana, Malawi and India, the cost of ART was 
perceived as a significant barrier to adherence to ART (Weiser et al, 2003, Kumarasamy 
et al. 2005; Oosterhout et al. 2005. For example, a formative qualitative study conducted 
in Chennai, India (Kumarasamy et al. 2005) which examined the barriers and facilitators 
of ART adherence identified cost of ART as the main barrier, which often resulted in 
patients having to sell their jewels and property or borrowing money to fund their 
treatment, and having to take self imposed “drug holidays” - in other words taking their 
medications only when they can afford to do so and stopping their medication when they 
can no longer afford it. Similarly, a study conducted in Botswana (Weiser et al. 2003) 
found the cost of ART to be perceived by both patients and health care providers to be 
the most significant barrier to ART adherence. Another cross sectional study conducted 
in Malawi to evaluate antiretroviral therapy results in a resource-poor setting by Van 
Oosterhout et al. (2005) concluded that one of the most important reasons for non-
adherence was personal financial reasons. The patient’s economic condition interfered 
with their inability to take treatment. 
 
A cross sectional study conducted among HIV positive individuals in Costa Rica to 
determine prevalence, predicators and reason for non-adherence to antiretroviral (Stout et 
al. 2004) cited difficulty in finding transportation to the clinic, in particular those that 
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were reliant on public transportation as this involves a significant amount of time, money 
to get to the clinic for consultations tests and prescribed antiretroviral drugs.   
 
Another study conducted by Uzochukwu et al. (2009) on determinants of non-adherence 
to subsidized anti-retroviral treatment was conducted in southeast Nigeria. Results from 
this study demonstrated that even though treatment was subsided ensuring that issue of 
cost of drugs was addressed other factors such as, treatment being a reminder of one’s 
HIV status and selling of ones’ own drugs to those unable to enroll in the project were 
key reasons for individuals not adhering to the treatment 
 
2.3.2. Stigma and discrimination 
In addition, various authors (Kumarasamy et al. 2005; Dahab et al. 2008; Weiser et al. 
2003) have citied stigma and discrimination as a significant barrier to ART adherence. 
Issues raised in relation to stigma were fear of disclosure of HIV positive status to others 
as this would result in rejection, negative reactions from others and stigmatizing the HIV 
positive person or their family members. This was seen as contributing to increased 
difficulty of taking medications in public, or of attaining ART adherence support from 
family members or HIV and AIDS - related care (Kumarasamy et al. 2005). In addition, 
Weiser et al. (2003) identified a non-supportive home and work environments as critical 
barriers to adherence.  
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2.3.3. Denial of one’s HIV status and feeling better as a result of taking ART 
A lack of acceptance of one’s HIV status was seen as barrier to adherence among PLHIV 
in developing countries. A qualitative study conducted in a South African workplace 
programme by Dahab et al. (2008) looking at patients & providers’ perspectives on 
barriers to and enablers of HIV treatment adherence reported that the main barriers were 
denial of existence of HIV or one’s positive status. As a result people on ART 
discontinued treatment, as they did not feel that it was necessary to continue with it.  The 
same study also found that PLHIV stopped taking their medication as result of feeling 
better. 
 
2.3.4. The influence of religious beliefs 
Although stigma is highlighted as a barrier in India and Africa, religion also seems to 
have a role in the stigmatization and discrimination of PLHIV. Religion plays a central 
role in many communities in Africa, shaping their beliefs, perceptions and attitudes. Zou 
et al. (2009) in their exploratory study conducted in Tanzania with parishioners (whose 
HIV status was unknown) attending Catholic, Lutheran, and Pentecostal churches in both 
urban and rural areas, which probed associations between religious beliefs and HIV 
stigma, disclosure, and attitudes toward ARVs treatment found that HIV related stigma 
was associated with the belief that HIV was a punishment from God and that people 
living with HIV were not living according to God’s word.  
 
However, findings from the same study indicated that although the majority of 
respondents believed that prayer could cure HIV, almost all the respondents indicated 
that they would begin treatment if they were HIV positive.  Findings from this study 
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indicated that refusal to take treatment was associated with a lack of education and a lack 
of knowledge of ARVs (Zou et al. 2009).   However a prospective observational study 
conducted by Wanyama et al. (2005) in Uganda, with PLHIV on ART, highlighted 
something different in particular: that 1.2% patients discontinued their ART as they 
believed that they no longer needed the treatment because of their belief that they had 
been spiritual healed. 
 
2.3.5. Forgetfulness, being busy and being away from home 
Sarna et al. (2006) and Stoul et al. (2004) both cited various reasons for ART clients 
missing doses.  In an exploratory study conducted in India by Sarna et al. (2006) on 
adherence to ART and sexual risk behaviour among ART clients, the reasons for missing 
doses included being busy with other things, forgetting and being away from home. Stout 
et al. (2004) have similar findings in their research citing forgetfulness, falling asleep 
through dose time, being busy with other things and being far from home as reasons for 
non-adherence. 
 
2.3.6. Substance abuse, side effects and severe depression 
Substance abuse such as alcohol was also a key barrier in adhering to ART among 
PLHIV on ART in the developing countries (Dahab et al. 2008; Weiser et al. 2003). In 
addition, side effects were also identified as a significant barrier to ART adherence 
(Dahab et al. 2008). Not only did alcohol and side effects impact on PLHIV’s ability to 
adhere to medication, lower adherence was associated with severe depression (Sarna et 
al. 2006).  
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2.3.7. Lack of food and resources to support ART adherence 
Studies have been conducted in various countries in Africa that cite lack of food and 
resources as a barrier to adherence among PLHIV (WHO, 2006; Weiser et al. 2003). For 
example, a multi-country study conducted in Tanzania, Botswana and Uganda showed 
that hunger and the need for more food in the initial stages of ART resulted in ART users 
missing the required doses (WHO, 2006). The study found that in many instances taking 
ARV made people hungrier and, due to lack of resources, to buy additional food some 
ART users resorted to taking their ART at times when food would be available (WHO, 
2006).   
 
2.3.8. Use of traditional medicine as barrier to adherence 
Dahab et al. (2008) in a study conducted in South Africa cited the use of traditional 
medicines as a barrier to ART adherence as it caused people on ART to stop treatment for 
the duration of the traditional treatment. 
 
2.3.9. Inadequate drug supply and long waiting times at the clinics 
Sarna et al. (2006) also found out that PLHIV missed doses as a result of pills being 
unavailable which was attributed to the public sector dispensaries running out of stocks. 
Similar findings of shortages of drugs were citied by Oosterhout et al. (2005), in a cross 
sectional study conducted in Malawi to evaluate antiretroviral therapy results in a 
resource-poor setting. Another study conducted by Uzochukwu et al. (2009) on 
determinants of non-adherence to subsidized anti-retroviral treatment was conducted in 
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southeast Nigeria. Results from this study demonstrated that even though treatment was 
subsidized ensuring that issue of cost of drugs was addressed other factors such as non 
availability of drugs at the treatment center resulted in PLHIV not adhering to their 
medication.  
  
Besides drugs being of out stock in the ART facilitates, a key issue around patient 
provider relations identified in developing countries was the issue of long waiting times 
at the clinic.  This resulted in people on ART being dissatisfied with the services being 
provided and were likely to stop going to the clinic to pick up their medication (Dahab et 
al. 2008). 
 
While it is has been acknowledged that the provision of drugs in many African countries 
has improved the lives of people, there are concerns about low adherence and the 
feasibility of scaling up ART programmes in resource-poor and constrained settings.  
Harries et al. (2001) argue that it is not just providing drugs that is important but 
unregulated access to drugs. Many countries in the Sub- Saharan Africa for example have 
challenges in the ability of the health systems to cope with the roll out of ART.  If this is 
not addressed, it could lead to widespread rapid emergence of drug resistant strains, 
increased treatment failure that reduces treatment options of individuals and leading to 
transmission of drug resistant strain of HIV.  
 
The authors Harries et al. (2001) argue that current provision of ART in Sub- Saharan 
Africa is characterized by having few health care workers skilled in the provision of and 
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management of ART, inadequate monitoring of viral load, immune status or side effects 
due to poor infrastructure, weak distribution and procurements systems and lack of 
monitoring systems to check drug adherence or drug effectives. Other concerns pointed 
out by the authors are about theft of medicines from public health facilities for sale in the 
market, shops, and private clinics and across the national boarders.  
 
2.4. Facilitators to ART adherence in developing countries 
Perceived benefits by PLHIV of taking ART were identified as facilitators to adherence 
(Kumarasamy et al. 2005; Sarna et al. 2006; Dahab et.al.2008).  Kumarasamy et al. 
(2005) identified facilitators of adherence to include perceived benefits of ART and 
proper adherence such as better health, living longer and gaining weight, perceptions 
about consequences of non-adherence and availability of social support (Kumarasamy et 
al. 2005). Another study conducted by Sarna et al. (2006) in India cited similar reasons 
for regularly taking medications. Patients in the study who reported never missing 
medications cited the desire to be healthy and avoid illness, the desire to live for their 
families and family support as important factors contributing in their taking medications 
regularly. In addition, doctor’s advice and emphasis on taking medications regularly were 
important factors to adherence.   
 
2.4.1. Use of strategies by PLHIV to support ART adherence 
The same study conducted by (Sidat et al. 2007) also identified commonly used strategies 
that PLHIV on medication used to remind themselves to remember to take their 
medication, including PLHIV receiving short messenger service messages (sms) in their 
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mobile phones organized by their care provider, setting up a mobile telephone alarm or 
table clock alarm and using pill boxes. 
 
2.4.2. Social support from friends, family and treatment supporters 
Dahab et al. (2008) also identified self-efficiency, social support, an effective adherence 
programme, the ability to fit ART into daily life schedule, and a desire to stay alive for 
the sake of others as facilitators to adherence (Weiser et al. 2003; Dahab et al. 2008).  In 
addition, Cortez et al. (2004) in the their research in providing ART in poor resource 
settings in South Africa cited and recommended that to attain high levels of adherence, 
community based ART initiatives need to have a strong-patient centered approach, 
comprehensive counseling which includes well trained lay counselors that provide one-
on-one counseling for people taking ART and peer support through support groups. 
Similarly Nachega et al. (2006) in their study conducted in South Africa identified the 
use of treatment supporters such as family members or friends being in contact with the 
patient and directly observing them as they take their medicine as a key strategy piloted 
in South Africa and recommended to minimize non-adherence were ART is being 
provided in resource –limited settings (Nachega et al. 2006).    
 
2.5. Barriers and facilitators identified as affecting ART adherence in 
Zambia  
Zambia provides a case of a setting with limited resources in Africa. The major concern 
in many resource-limited settings is the potential of emergence of drug resistant viral 
strains. Therefore to prevent this optimal adherence is required. Only a few studies have 
been conducted in relation to ART and adherence in Zambia to date, however. The first 
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study  explored experiences of HIV and AIDS related treatment in urban and rural setting 
in 2002 and 2003 (International HIV and AIDS Alliance 2003), and the second study 
focused on  the experiences of treatment users and heath care workers (International 
HIV/AIDS Alliance (2004) in Zambia. Both studies focused on urban settings, although 
the community consultations had a component on a rural setting, and thus do not 
necessarily address the potential barriers and facilitators faced by PLHIV in rural areas. 
To the best of my knowledge there is very little information is available on the factors 
that contribute to the levels of adherence in Zambian rural communities.  
 
The study on experiences of treatment users and heath care workers (International HIV 
and AIDS Alliance, 2004) was a preliminary baseline research study conducted in Lusaka 
and Ndola districts in August 2004.  The International HIV/AIDS Alliance study found 
that treatment users faced various barriers to treatment including costs of treatment and 
travel, lack of information on services being provided and information on antiretroviral 
drugs and how they work. The same study identified stigma and discrimination as another 
main barrier as this contributed to people not to being able to access treatment or care for 
fear of being perceived to be HIV positive (International HIV/AIDS Alliance, 2004). 
These findings are similar to findings in other parts of developing countries. This study 
also suggested that whilst there was a high level of adherence in the early stages of 
treatment, interviewees showed little indication of how best they could maintain 
adherence later on (International HIV/AIDS Alliance, 2004). 
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As noted in other developing countries, PLHIV taking medication in Zambia have used 
various reminder strategies to support the uptake of ART.  The International HIV/AIDS 
Alliance et al. (2007) identified strategies used to promote adherence included patients 
using an alarm, clock and radio to remind one on when to take the drugs, children, family 
members including spouses and home based care workers reminding patients to take their 
drugs (International HIV/AIDS Alliance et al. 2007). 
 
2.6. Conclusion 
This literature review sought to provide an understanding of barriers and facilitators to 
adherence among people living with HIV in developed and developing countries.  The 
literature suggests that whilst some factors - such as side effects, patients’ attitudes, 
beliefs, and fear of disclosure - contribute to non-adherence in both developed and less 
developed countries, there are some unique factors that contribute to non-adherence 
among people living with HIV in the developing world. For many developing countries, 
particularly in the Southern Africa these factors include costs associated with treatment, 
stigma and discrimination, being away from home, running out of pills and long waiting 
times at the ART facility.  
 
Facilitators to adherence in both developing and developing countries included 
knowledge of medication, belief in the treatment and social support from friends, family 
members. More specific to developing countries such as countries in Africa, nutritional 
support and use of treatment supporters contributed to individuals adhering to treatment 
regimes.   
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However, it is also clear from the literature review that the issues of adherence to ART, 
particularly in rural Southern Africa, are still not adequately explored. Gil et al. (2005) in 
their work on ART adherence in sub-Sahara Africa argue that most African adherence 
studies to date have limited their scope to reporting on adherence rates and population 
risk factors.  Not much is focused on qualitative research to determine why a patient is 
not being adherent and examining the factors that foster sustained adherence. As Zambia 
is working towards meeting the universal access to treatment by 2010, there is a need to 
identify and understand the factors that can contribute to adherence among people living 
with HIV – specifically in rural settings.  In light of the discussion in this chapter, the 
researcher has tried to explore this further through this study.  
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CHAPTER THREE 
METHODOLOGY 
 
3. Introduction 
The aim of this study was to identify the potential barriers and facilitators of adherence to 
antiretroviral treatment among adult PLHIV in rural Chongwe district of Zambia and 
provide recommendations on how best to support ART adherence in a rural context.  The 
following were the objectives of the study: 
 
1. To explore with PLHIV on ART in the rural district of Chongwe, their 
knowledge, perceptions and beliefs about the importance of ART 
2. To explore with PLHIV on ART   the barriers and facilitators to ART adherence 
and how best to offer PLHIV ART adherence support. 
3. To explore with health workers and ART treatment supporters associated with St. 
Luke’s Mission Hospital in Chongwe the perceived barriers and facilitators to 
ART adherence among PLHIV and how they can best offer PLHIV ART 
adherence support. 
4. To synthesize study findings and recommendations on how best to support ART 
adherence and  implementation of ART adherence strategies; specifically in the 
context of a rural district. 
 
3.1. Study Design  
The researcher conducted a explorative qualitative study. A qualitative study was used in 
order to gain in-depth insights into barriers and facilitators to ART adherence among 
 
 
 
 
 25 
PLHIV in rural areas. The perceptions, opinions and experiences of PLHIV on ART 
regarding the barriers and facilitators influencing ART adherence were explored using 
the qualitative methods of in-depth interviews and focus group discussions (FGDs).  
Similarly, interviews and FGDs were conducted with health workers at the Health facility 
and ART treatment supporters respectively to explore how they can offer appropriate 
ART adherence support to PLHIV in a rural health facility. 
 
3.2. Study Population 
The study was conducted at St. Luke Mission Hospital in Mpanshya village and two 
other villages, namely Rufusa and Chimusanya. These two villages were part of the ART 
outreach centres for the health facility. These two villages were selected out of a group of 
seven outreach centers (villages) associated with the health facility on the basis that these 
villages had functional support groups. These support groups met regularly and it was 
therefore anticipated that the groups would provide rich perspectives on barriers and 
facilitators to adherence. The study population consisted of the following: 
PLHIV interviewees: Eight PLHIV (four women and four men) on ART, one female 
PLHIV on ‘pre ART’2 were interviewed through in-depth interviews. Demographic 
characteristics of PLHIV are summarized in chapter four (the results section).  
 
Characteristics of PLHIV support group members
3
  
                                                 
2 PLHIV on pre ART have been enrolled to start accessing ART but have not yet started. These are usually 
provided with counseling, information on ART and monitored by the health facility. 
3 A support group in Zambia is usually made of up people living with HIV and AIDS and is normally 
registered with the Network of people living with HIV and AIDS in Zambia. 
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Two FGDs were conducted, with a total of 23 PLHIV from two support groups in 
Rufunsa (13 PLHIV) and Chimusanya (10 PLHIV) villages. The support groups mainly 
constituted PLHIV that had tested positive for HIV and knew their status. The FGDs 
therefore, included people on ART treatment and those not yet on treatment. The 
researcher did not get detailed demographic characteristics from these FGD members.  
 
Treatment supporters: In addition, nine (five men and four women), caregivers4 who 
are treatment supporters from Chimusanya village, participated in a FGD. The group 
included a pastor, two teachers, a PLHIV and five community members, who were 
subsistence farmers. The treatment supporters were all trained and were linked to the 
ART facility at St Luke Mission hospital. The treatment supporters’ key role was to 
conduct home visits in the community to support PLHIV placed on treatment and the 
PLHIV’s families through counseling, providing information and referrals to health 
facility when needed.    
 
Key informants : The health facility has a total of 13 health care workers. Five of these 
(two females and three males) were interviewed and formed part of the ART facility that 
provided ART services in the community. The interviews with key informants were 
conducted to compliment the information from the in-depth interviews with PLHIV. The 
following were the Informants: 
                                                 
4 A caregiver in this study is a trained care provider who provides health services such as counseling, 
support of adherence, and making referrals at the community and home level. This caregiver or provider is 
usually linked to community and home based care programmes supported by NGOs, FBOs and other 
organizations in this case the caregivers are linked to the health facility. 
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• The ART nurse responsible for the hospice, coordinating the ART facility and 
outreach activities. 
• The counselor, providing counseling for testing care and support.  
• The hospital nurse supporting the ART facility. 
• The Environmental Health Technologist responsible for supporting adherence, 
care and support at the health facility.  
• A Doctor on short-term placement responsible for screening patients at the health 
facility. 
 
3.2.1. The selection process for in-depth interviews with people living with 
HIV  
A meeting was held with key hospital staff in December 2008 to explain the purpose of 
the research and discuss how best PLHIV interviewees ought to be sampled. Based on the 
random sampling criteria identified by the researcher, hospital records (specifically those 
with registrations of ‘pre ART’ services and ART services) from all the 7 villages or 
outreach centres were provided by the health facility to the researcher in December 2008.  
There were a total of 731 people living with HIV and on ART that were clients of the 
facility, attending the hospital and being followed up in the villages. These were seen by 
staff and followed up in the villages using the outreach activities. Interviewees were 
randomly sampled from this original register list, where an initial 25 potential 
interviewees were randomly selected.  This provided the researcher with a range of 
people who had various experiences of ART adherence. The researcher then worked with 
the health worker to trace and identify the homes of the randomly selected PLHIV over a 
period of one day in December 2008.  
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From the initial list of 25 PLHIV randomly selected, the researcher ended up with a list 
of 11 key potential interviewees5. The original list of 25 was reduced to 11 as some of the 
potential interviewees could not be interviewed due to various reasons such as their death 
or unavailability at their homes at the time for the interview. Others could not be accessed 
due to the fact the villages were very far from the health facility (for example, 120km) 
and the poor road networks and heavy rains made the way to their villages impassable.  
 
From this second list of 10 PLHIV on ART and one on pre-ART, the researcher was only 
able to interview three PLHIV (one female and two males) from Mpashaya village. The 
remaining PLHIV on the list could not be interviewed because some were not available 
for the interview because they had traveled to the city (Lusaka) and another PLHIV, who 
was identified as an alcoholic, could not be located. Furthermore the ART center 
confirmed that the latter person was not adhering as a result of alcohol abuse. As data 
collection was conducted during December, one of the rainy season months, the 
remainder of selected PLHIV could not be assessed due to heavy rains, which made the 
road to their villages impassable.  
 
To ensure that saturation could be reached, an additional five PLHIV were purposively 
selected from the two FGDs conducted in Rufusa and Chimusanya villages with support 
groups of PLHIV– which are described in the next section. Of the five PLHIV, two 
PLHIV interviewees (one female and one male) were selected from the first FGD with a 
support group held in Refusa village. The remaining three PLHIV (two females and one 
                                                 
5 10 PLHIV were on ART and one PLHIV was on Pre-ART 
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male) were selected from the second FGD with a support group held in Chimusanya 
village.  The selection of the five additional PLHIV interviewees from these FGDs was 
done on the basis of information gathered during the FGDs. The PLHIV were chosen 
because they did not contribute much during the FGDs and were willing to participate in 
the in-depth interviews. The FGDs with support groups of PLHIV were conducted on 
29th December 2009.  
 
An additional PLHIV was identified for an in-depth interview during the FGD with the 
treatment supporters in Chimusanya village. During the conversation with treatment 
supporters, it was highlighted in the FGD, that a female PLHIV had stopped taking drugs 
due to religious reasons. As this was a unique case that would provide interesting insights 
on adherence, with support of the treatment supporter linked to this PLHIV and the 
Environmental Health Technician, an appointment was set up with the PLHIV to conduct 
the interview at their home on the same day of 29th December 2009. This interviewee did 
not participate in any of the FGDs with support groups. 
 
3.2.2. The selection process for key informants – Health care workers  
From a total of 13 health care workers working within the hospital, six key informants 
that worked in the ART facility were identified of which five were interviewed. These 
worked both in the hospital and were part of the ART outreach programme (ART mobile 
clinic).  One staff member declined to participate in the interviews because he did not feel 
comfortable to participate in the process. The interviews were conducted on 28th 
December 2008 with the following informants: 
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• The ART nurse responsible for the hospice, coordinating the  ART facility and 
outreach activities 
• The counselor, providing counseling for testing care and support.  
• The hospital nurse supporting the ART facility. 
• The Environmental Health Technologist responsible for supporting adherence, 
care and support at the health facility  
• A Doctor on short term placement responsible for screening patients at the health 
facility 
 
3.2.3. The Selection process for focus group discussions with support groups 
of PLHIV and treatment supporters 
A total of three FGDs were held with 2 support groups of PLHIV (23 PLHIV in total) 
and one with nine treatment supporters in Rufunsa and Chimusanya villages. The FGD 
with treatment supporters was held in Chimunsanya village. 
 
Each of the seven villages had a support group of PLHIV and that was supposed to meet 
once a week. Given that the initial decision was to work with two support groups of 
PLHIV, support groups of PLHIV were purposively selected with assistance from the 
ART nurse and the Environmental Health Technician.  The two villages were selected 
because they had functioning support groups.  
 
The ART nurse and the Environmental Health Technician were also responsible for 
selecting treatment supporters. As Chimunsya village was already selected for conducting 
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a FGD with a support group, treatment supporters were therefore selected from the same 
village.  
 
3.3. Data Collection 
Data was collected in the month of December over a period of three weeks, from the 11th 
of December to 29th December 2008. Data was collected through in-depth interviews 
from nine PLHIV, five key informants and from three focus group discussions (two with 
PLHIV support group members and one with treatment supporters on 29th December 
2008). The researcher mainly conducted the interviews with PLHIV, key informants and 
FGDs. The researcher also had support from another colleague from Zambia OPEN 
University. This colleague observed the interviews and FGDs and also supported with 
data collection; for example, he specifically facilitated discussions with one support 
group of PLHIV in Chimusanya village.  
 
The ART nurse and the Environmental Health Technician were responsible for 
coordinating and ensuring that time was booked to meet with the treatment supporters 
and the support groups. The ART nurse was also responsible for working with support 
groups in the villages and assisted the researcher to identify functioning support groups. 
The Environmental Health Technician who was a staff at the ART facility was assigned 
to assist the researcher to identify homes of interviewees, setting up meetings and 
introduce the researcher.  
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3.3.1. The procedure for conducting in-depth interviews with PLHIV and 
interviews with key informants 
In relation to the PLHIV interviewees the researcher, with assistance from the 
Environmental Health Technician, visited some interviewees in their homes and 
arrangements were made to have the interviews done in a private place at their home. 
Three in-depth interviews were conducted on the 26th of December 2008 and six in-depth 
interviews were conducted on the 29th of December 2008. The researcher conducted four 
interviews at the houses of the interviewees as this was much easier to arrange and the 
setting was comfortable for the interviewees. However this posed a challenge for the 
researcher who was sometimes required to provide details about the meeting to other 
members of the family who were present during the visit. Although family members 
knew the status of their HIV positive family members, to ensure confidentiality for 
interviewees, the researcher emphasized that she was a student who came to learn from 
the experiences of their family members. The other five in-depth interviews were 
conducted at the health facility in Rufusa and at a school in Chimusanya respectively as 
these PLHIV were selected from the support groups of PLHIV that had come for FGDs. 
 
In addition, the researcher had to make a courtesy call to the local headman in Mpashaya 
village so that the purpose of the visit could be explained to the traditional leadership in 
the community6. The researcher explained to headman that it was a learning visit that will 
contribute to the studies that researcher was involved in and this was part of the 
requirement of the studies the researcher was doing.  
 
                                                 
6 Paying a courtesy call visit on the local leadership is a sign of respect and it is encouraged within the 
communities. 
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For in-depth interviews, the local language Njanja was mostly used as this was preferred 
by the interviewees. The interviewees were informed about the study in the local 
language and assured that their participation or non-participation would not impact on the 
quality of care they received at the hospital. The participant information sheet (Appendix 
8) consent information (Appendix 10) was given to everyone taking part in the research, 
read with the interviewees and consent regarding understanding and willingness to 
participate in the research was sought before the interview.  
 
Once consent was given, each PLHIV interviewee was given a code number which as 
used in the consent form. Individual, face-to-face interviews were conducted using a semi 
structured interview guide. The interviews took approximately one and half to two hours 
depending on the ability of the interviewee to articulate themselves and their openness to 
provide detailed information during the interviews. In total, in-depth interviews were 
conducted with nine PLHIV as the researcher believed at this point saturation had been 
reached and no new information was emerging from the interviews. 
 
The interview guide for PLHIV was pre-tested with three PLHIV on ART at a peri-urban 
community based organization in Lusaka prior to conducting the research. The interview 
guide was refined based on feedback received to ensure that questions were culturally 
appropriate.  
 
The interview questions with interviewees were mostly open ended and included a focus 
on demographic factors, understanding of adherence and antiretroviral drugs, perceived 
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benefits of ART, possible reasons for non and good adherence, types of support 
mechanisms available, and participants thoughts on how adherence could be facilitated, 
supported and sustained. (An interview guide for in-depth interviews is contained in 
Appendix 4). All interviewees were thanked at the end of the interviews and an amount 
of K10, 000 ($2) was given, to thank the nine PLHIV.  
 
Similarly, with the five interviews with key informants, appointments with each one of 
them were made and interviews were held in their homes on the 28th of December 2008. 
A participant information sheet was provided to staff and consent was sought before 
interviewing them. The interview questions with key informants were mostly open ended 
and these included demographic factors, type of training they had received, possible 
reasons for non-and good adherence among PLHIV, types of support mechanisms 
available for PLHIV on ART, and informants thoughts on how adherence could be 
facilitated, supported and sustained (See Annex 5 for interview guide).  
 
3.3.2. The Procedure for conducting Focus Group Discussions  
 In relation to FGDs, a total of three FGDs were held. Two FGDs were held with 2 
support groups of PLHIV and one with treatment supporters. The health worker, a 
counselor from the ART facility, who as part of their job has the responsibility to 
coordinate support groups and work with treatment supporters, supported the researcher 
in identifying the support groups and the group of treatment supporters. PLHIV and 
treatment supporters were informed of the FGD meeting a week prior to the FGDs 
meeting dates. The counselor liaised with the chairperson of the support groups and asked 
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if the researcher could meet the 2 support groups of PLHIV on 29th December 2008 and 
treatment supporters on 29th December 2008. As these were not the normal meetings days 
for the support groups, these meetings were specifically set up to enable the researcher 
conduct the FGDs. These meetings were arranged at a central place within the selected 
villages.  
 
The first FGD was conducted with a support group of 13 PLHIV at the local health centre 
in Rufusa village, and the second and third FGDs (with a support of 10 PLHIV and nine 
treatment supporters respectively) were conducted at a local school in Chimusanya 
village. An interview guide was used for all the FGDs.  All the FGDs explored issues on 
ART and adherence and tried, through the group discussion process, to ascertain what the 
possible barriers and facilitators to adherence among PLHIV were. The FGDs were also 
designed to provide insight into what they (PLHIV and the treatment supporters) 
perceived would be necessary support-to-support adherence among PLHIV in rural 
settings (See Appendix 6 for FGD guide with support groups and appendix 7 for FGDs 
with treatment supporters).   
 
Before the FGDs were conducted a participant information sheet (Appendix 9) was given 
to all participants of the FGDs and an explanation was provided about the research in 
both English and Njanja the local language. Participants were asked if they understood 
what was being asked of them and were given an opportunity to ask questions and given 
an option not to participate. Consent was given verbally and the chairperson of the 
support group signed on behalf of the group. The need for confidentiality was explained 
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emphasizing that issues discussed in the FGDs were not to be taken beyond the 
discussions.  
 
English and the local language Njanja was used through out the discussions. The 
discussions took approximately one hour to one and half hours. An amount of K10, 000 
($2) was given, as transport reimbursement to all the participants in the FGDs. Snacks 
were also provided for participants in the FGDs.   
 
3.4. Validity  
To ensure rigour, data sources were triangulated through different qualitative data 
collection methods: individual in-depth interviews with PLHIV, the FGDs with PLHIV 
support group members, ART treatment supporters and interviews with key health staff at 
the ART facility.  
 
During the process of each interview, the researcher presented a key summary of 
discussions points at regular intervals to allow validation from key interviewees.  The 
researcher also took field notes during the in-depth interviews and FGDs and these 
sessions were transcribed. Each day, the researcher documented reflections and 
observations made through out the process of data collection and the analysis exercise. 
The researcher also used peer review and member checks. At the end of each day, the 
researcher had a briefing session with the colleague from Zambia OPEN University.  
Through this process, questioning of research findings was done and this enabled the 
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researcher to gain additional insights on facilitators and barriers to ART adherence in 
rural communities.  
 
3.5. Data Analysis 
Interview questionnaires and field notes were reviewed several times.  Data analysis 
started during the data collection exercise. A thematic analysis approach was used.  
Based on the research objectives some broad themes or categories related to barriers and 
facilitators to ART adherence were identified by the researcher and the assisting 
researcher during the data collection exercise – along with the proposals interviewees and 
key informants made about their desired adherence support.  These formed the core 
themes around which all the data was clustered. Relationships between these categories 
were then compared, and inconsistencies, variations and new insights identified.  Direct 
quotations have also been used during the write up of the report. 
 
3.6. Ethical Considerations 
After the University of the Western Cape approved the protocol, permission to conduct 
the research at St. Luke Mission Hospital in Chongwe district was requested through the 
hospital management team.  In addition, the researcher was asked to send the protocol to 
the ethics committee at University of Zambia for further approval (see Appendix K for 
the approval letter from the Ethics Committee). 
 
As per custom in many villages, the researcher also made a courtesy call on the local 
headman in Mpahasya village. This did not in any way impact on the confidentiality. The 
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purpose was to greet and let the village headman know that the researcher was visiting 
his community to learn more on issues pertaining to ART and adherence in the 
community. 
 
Participation in this research was voluntary and participants were provided with 
information about the research. Participants in the FGDs were informed by the health 
worker a week prior to the meeting with FGDs. Participants were asked for their 
informed consent prior to the interviews commencing.  The identities of the PLHIV in-
depth interviews were protected both during the interview phase and in the write up of 
the results by assigning codes to participants, which ensured their anonymity. In the event 
that the participants needed assistance (such as counseling support or a referral) 
arrangements were made with the relevant staff at the hospital to provide the required 
support and follow up. It was important that the researcher minimized any harm caused 
during the interview process. In addition, information on PLHIV support services for 
participants who might need additional counseling or support following the interview was 
provided by the researcher and identified concerns raised during interviews and FGDs 
were fed back to the ART facility.   
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CHAPTER FOUR 
RESULTS 
 
4. Introduction 
This chapter reports on findings from in-depth interviews with PLHIV on ART, key 
informant interviews with health care workers, focus group discussions with caregivers 
(treatment supporters) and two support groups of PLHIV. The results focus on the 
following themes and issues:  
• Demographic information about PLHIV on ART that participated in the in-depth 
interviews. 
• The knowledge, perception and opinions about the importance of ART treatment 
from the perspectives of PLHIV.  
• The barriers that PLHIV have either experienced or anticipate will affect their 
level of ART adherence. 
• The facilitators that PLHIV have either experienced or anticipate will affect their 
level of ART 
• Suggestions from interviewees, support group members, treatment supporters and 
health care workers of what can be done to improve the adherence support 
currently offered to PLHIV on ART adherence at ST Luke Mission Hospital, in 
Chongwe district.  . 
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4.1. Description of PLHIV that participated in individual interviews  
Basic demographic information about the nine PLHIV consisting of five females and four 
males– that participated in the in-depth interviews was collected in order to provide some 
background information on the interviewees. In-depth interviews were held with PLHIV 
from three villages, the ART facility is located at St Luke Mission in Mphashya village. 
Table 1 below summarizes these demographic characteristics:  
 
Table 1: Demographic characteristics of PLHIV interviews 
Number  Belonging 
to a 
support 
group  
Sex Age Marital 
Status 
Education 
attained 
Occupation Length of 
time on 
ARVs  
Mode of 
transport 
to ART 
clinic 
Duration of 
travel to 
ART clinic 
Mphashya Village 
1 Yes  F 22 M Secondary Selling 
alcohol 
Nthemba7 
Not yet8 On foot 20 minutes 
2 Yes M 32 M Secondary Farming 1 year & 
1month 
On foot 30 minutes 
3 No M 40 M Primary Watchman 
and farming 
3 months On foot 15 minutes 
Rufunsa Village 
4 Yes F 27 M Primary Farming 3 years Borrows a 
bicycle 
2 hours 
5 Yes M 38 M Primary Farming, 
piece work  
1 year & 6 
months 
On foot  2 hours 
Chimunsanya village 
6 No F 26 S Primary Selling 
cassava, 
poultry 
farming 
4 years Bicycles 3 hours 
7 Yes F 30 S None Farming, 
piece work9 
2 months On foot 3 hours 
8 No F 42 M Primary Farming and 
selling 
flitters 
4 years On foot 
(Mobile 
clinic) 
10 minutes 
9 Yes M 44 S Secondary Farming  1 year On foot 
(Mobile 
clinic) 
30 minutes 
 
 
                                                 
 
7 Nthemba in the local language is a local shop or kiosk 
8 PLHIV had been on Pre-ART since 2006. This interviewee was receiving introductory information, 
counseling and monitoring before initiating ART.   
9 Working on other people’s farms which included jobs as labourers such as weeding, planting and digging  
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As can be observed from the table above, the nine interviewees were aged between 22 
and 44.  Five of the interviewees had attained primary education and three, secondary 
education. 
4.2. Knowledge, perceptions and opinions on the importance of ART 
treatment 
4.2.1. The perceived benefits of taking ARVs  
When asked what they knew about ARVs and the purpose of taking ARVs, many of the 
PLHIV participating in the in-depth interviews suggested that ARVs made them 
‘stronger’ by ‘boosting’ the body, providing their bodies with renewed energy to ‘fight 
the virus’ and thus, prolonging ‘life’. Two of the nine PLHIV interviewed described the 
benefits of ART as such:   
… [ARVs] make the virus weaker and help me get 
stronger, gives me energy. 
Female PLHIV, interviewee # 4 
…because it [ART] boosts the body, the body has energy, 
[and] strength and [it] can fight the virus.  
Male PLHIV, interviewee # 9 
One PLHIV that participated in the in-depth interviews particularly acknowledged that 
the ARVs did not only give him “long life” but it improved his life and at least ensured 
that he would be present to watch his children grow- as stated in the following words 
…they [ART] give long life, this ensures that the children 
can grow and I do not leave them young. 
Male PLHIV, interviewee # 2 
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The perception that ARVs prolong life was also highlighted during the FGDs with the 
two support groups of PLHIV. Participants in these FGDs argued that ARVs improved 
their health and strengthened their immune system by keeping their CD4 counts high. 
The group indicated that this reduced the “HIV viruses” in their bodies, making them feel 
better and stronger. As a FGD participant summarized below: 
The [ARVs] boosts the CD4 count to go high, this helps to 
 Reduce the HIV virus and improves our lives so that we  
can go pa songolo [local term to mean moving forward].  
FGD participant in Rufunsa 
 
4.2.2. Knowledge about names and how ARVs are supposed to be taken 
Of the eight PLHIV on ART and who were interviewed individually only four were able 
to name the drugs they were taking. Of these four, three said they were on 
Nevirapine/Zidovudine/Lamivudine while one was on Truime 30. At the time of the 
study, based on the Zambia National guidelines on ART, all these drugs were part of the 
first line regime. The other four interviewees were not able to name the ART drugs they 
were taking – although one mentioned that ‘he was not sure but thought he was taking 
Truime 30’ and two other interviewees could describe the color of the drugs they were 
taking: 
 I cannot remember the names but the drugs were yellow and white.  
       Female PLHIV, interviewee # 4 
 I do not know the names but they [drugs] are white and I have two bottles.  
       Female PLHIV, interviewee # 7 
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All of the PLHIV, apart from one understood the importance of taking their medication at 
the prescribed time(s). However, one interviewee, who mentioned taking medicine in the 
morning and evening, did not seem to know what he was taking specifically and for how 
long he was supposed to take the medicine: 
…I have no idea what I am taking. I was not told about the drugs, 
information was not adequately given to me. I take my medicine at 
6:00 hours in the morning and 18:00 hours in the evening. I do not 
know how long I have to take them. I was told when I started taking 
the medicine that I will take for 4 months. 
           Male PLHIV, interviewee # 3 
 
Pre-ART therapy is supposed to prepare PLHIV to initiate treatment. The study revealed 
that in the nine interviewees the PLHIV who had attended pre-ART for two years had 
areas where they lacked understanding.  Although she understood that ARVs were to be 
taken for life, she did not know how they were to be taken. As stated in the following 
words: 
I do not know if you need to take 1 or 2 tablets a day, I am not sure,  
[but] you are not suppose to stop [taking the medication].  
     Female PLHIV, interviewee# 1 
 
When asked if they were on any other medication besides ARVs, seven of the nine 
PLHIV interviewees said that they took Septrin. Four of those on Septrin said it was 
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meant to protect them from coughs and Tuberculosis. One interviewee on Septrin had this 
to say about the drug: 
…I take Septrin once a day so that I should not cough, this reduces 
the cough and I started taking this since I was [diagnosed HIV] 
positive. 
Male PLHIV, interviewee # 5 
 
An interesting finding from the participants in FGDs with supports group of PLHIV in 
Rufunsa was that were of the impression that those not belonging to any support group of 
PLHIV had a tendency to mix medication.  and did not understand the role of ARVs..  
These “Outsiders” or non-support group members were perceived to consult traditional 
healers and, were therefore, taking traditional medicines together with conventional 
(ART) medicine, which the ART facility did not encourage. As a FGD participant in 
Rufunsa Support Group said:  
…Those that do not belong to a support group, go to the traditional doctors, these 
do not understand and do not know. 
PLHIV FGD participant, Rufunsa support group  
 
4.3. Reported non-adherence and knowledge of the consequences of 
skipping medication 
When asked whether they had missed a dose of their medication in the past month, most 
of the interviewees indicated that they had not missed any dose and only two shared how 
their treatment regime had been interrupted.  In the first instance, a male interviewee 
shared how he had missed taking his medication on one occasion because he had felt ill 
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and had sought help at the local clinic. However, because of this he was not able to return 
home to access his medication for that day: 
…I am a watchman, was working over-night, and went to 
the clinic last night [the night before]. I was not feeling 
well and missed a dose in the morning as the medicine was 
at home.  
Male PLHIV, interviewee # 3 
 
In the second instance, a female interviewee said she had completely stopped taking 
drugs on the doctor’s recommendation because she experienced frequent side effects. She 
explained this as follows:  
Due to side effects, I stopped taking the drugs, as the clinical staff 
stopped me from taking the drug. I need to get back [to the 
Hospital] and get a blood test. 
Female PLHIV, interviewee # 6 
 
This PLHIV indicated that she had been off medication for a month before the interview. 
However, before the interview, a treatment supporter identified this PLHIV during the 
FGD with treatment supporters as having stopped medication due to supposedly a 
Pentecostal pastor encouraging her to stop her medication. What was surprising for the 
researcher was that the PLHIV in question had indicated that staff at the hospital stopped 
her from continuing her medication. 
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Some interviewees seemed not to understand the consequences of skipping medication.  
As seen below, three out of the eight PLHIV individual interviewees on treatment 
admitted they did not know what would happen if they failed to take treatment: 
I do not know what happens when one does not take the medicine. 
 
      Female PLHIV, interviewee # 7 
 
I hear from people that you can die quickly.  
 
      Female PLHIV, interviewee # 8 
 
Hmm… I do not know (holding his head).  
 
Male PLHIV, interviewee # 3 
 
4.4. Accessing information about ARVs  
It was clear from PLHIV participating in the in-depth interviews that the health facility 
was their primary source of information about ARVs. Seven of the nine interviewees said 
they accessed this information specifically from a counselor or doctor at the health 
facility who provided them with both counseling and information regarding the drugs. As 
a female PLHIV interviewee stated:  
…Before I started taking the ARVs, I did not know anything about this.  
When I started taking the drugs that is when I knew about the drugs.  
       Female PLHIV, interviewee # 4 
 
Another interviewee said that he was encouraged to go for an HIV test after his wife fell 
ill and was admitted to hospital.  Whilst at the hospital he learnt about ARVs: 
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I was in hospital and my wife was sick. When my wife was tested, 
I also tested and I was told that I am positive. The counselor at the  
ART clinic [then explained to] me about ARVs. 
  Male PLHIV, interviewee # 5 
 
Of the two other PLHIV, one indicated that they got the information from the community 
counselor and the other got information from their support group.  Although during the 
in-depth interviews the health facility was highlighted as a major source of information 
about ARVs and HIV and AIDS, the FGDs with support group of PLHIV tended also to 
emphasize the importance of support groups in providing information, support and 
encouragement to PLHIV – including information about ARVs.  A FGD participant 
summarized the role of support groups as follows:  
Being in support group helps me, as we share the challenges in the 
groups, this removes fear… If I have a problem I go to my [support 
group] friends for support. 
    FGD participant, Rufunsa Support group 
4.5. Barriers that PLHIV have either experienced or anticipate will 
affect their level of adherence to ART. 
Several themes emerged from the in-depth interviews with PLHIV on ART, the FGDs 
with PLHIV support group members, 13 from Refunsa village and 10 from Chimusanya 
village. The barriers ranged from side effects to religious beliefs and are described below: 
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4.5.1. ARV Side effects  
PLHIV cited side effects as one of the negative experiences associated with taking ARVs. 
All the eight interviewees on ART said they had experienced several side effects, such as 
pain in their feet, swelling of feet, loss of appetite, dizziness and skin rashes. However 
seven of them indicated that this did not cause them to stop taking the ARVs. Support 
group members, treatment supporters as well as heath workers also highlighted side 
effects as a key barrier to adherence to medication.  A FGD participant had the following 
to say: 
Side effects make some to stop taking ARVS, although one 
should continue taking the drugs and not stop. If they feel 
sick they should go to the clinic 
FGD Participant, Rufunsa Support group 
 
Despite indications from interviewees and PLHIV in support groups that one should not 
stop taking medication, there were obviously instances where patients defaulted. For 
example, one female PLHIV interviewee said she had stopped taking the ARVs because 
of the side effects.  
 
4.5.2. Improved health and lack of understanding of the importance of 
adherence 
During the in-depth interviews PLHIV said that some PLHIVs in the community stopped 
taking drugs because they felt better and healthier and that their quality of life had 
improved. A health worker supported this phenomenon, emphasizing what a challenge it 
was to ensure that PLHIV continued to take their treatment was when they felt healthier: 
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…when PLHIV are sick they will adhere, but when they feel better 
they "forget"…They are hard nuts to crack  
ART clinic staff, St Luke Mission Hospital 
 
4.5.3. Shame and fear of embarrassment  
Shame and embarrassment associated with taking ARVs was also highlighted as 
contributing to PLHIVs not adhering to treatment.  PLHIV’s fear or shame and 
embarrassment acting as a barrier to ARV treatment adherence, seems to stem from their 
concern that community members may be able to identify them as a person having HIV 
through noticing that they are taking medication (ARVs) associated with HIV infection. 
PLHIVs said they feared they would be laughed at if seen taking ARVs and, therefore, 
did not to take their medicine at the appropriate time or, in some cases, at all. 
 
A male PLHIV shared how he anticipated the community would treat him if they knew 
he was taking ARVs and how this influenced his behaviour vis-à-vis medication:  
 I used to experience side effects such as legs swelling. Since it was the first time 
taking the medicine I used to feel shy to take the medicine so I took the drugs in 
hiding [because] I feared being laughed [at] by others - especially people in the 
community. 
                          Male PLHIV, interviewee # 9 
Similarly, FGDs with support group members also cited embarrassment as sometimes 
hindering PLHIV in the community to adhere to drugs.  The fear of being labeled by the 
community was raised as a barrier to taking medication. Terminologies used by people in 
communities such as “kanayaka” (Nyanja for the HIV virus has hit her or him) were 
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often heard by themselves when reference was made to PLHIV.  Consequently some 
PLHIV generally hid from neighbours, community members and family members that 
they were on medication. They were also afraid of taking their ARVs in public.  
 
PLHIV in FGDs in Rufunsa and Chimusanya villages also identified stigma in the 
community as a factor contributing to non-adherence to treatment among other PLHIV in 
the community. Consequently PLHIV sometimes ended up going to ART centers outside 
their communities for fear of being seen by people. A male PLHIV support group 
member summarized it, this way: 
Stigma and discrimination is still a problem. Some PLHIV 
usually have neighbors laughing at them saying that 
"kanayaka" [so] they cannot manage to take them [ARVs] for 
life [because of] being laughed at. And also if they – PLHIV- 
feel sick they should go to the clinic.  For example, people feel 
shy [to do this] as people will laugh at them and because 
people do like gossiping. 
FGD participant, Rufunsa Support group 
 
4.5.4. Alcohol abuse as a barrier to ART adherence 
Although the PLHIV interviewees did not cite alcohol abuse as hindering adherence 
among them, alcohol abuse was citied by the two FGDs with the support groups and key 
informants as an emerging problem within the community. For example,  a male PLHIV 
sampled for the interview could not be located at the time of the interview and the ART 
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clinic staff suggested he might be too drunk to interview. It was later also discovered that 
he was a defaulter,  and the reason he had defaulted on medication was due to his high 
alcohol intake.  
 
PLHIV from the Rufunsa FGD argued that PLHIV within the community who abused 
alcohol found it difficult to adhere to treatment. They  had difficulties remembering to 
take drugs and were, therefore, unable to adhere to treatment. Two health workers at the 
health facility also agreed with this conclusion.  This problem seemed largely prevalent 
among males. As a health worker noted,  
Use of alcohol is a problem…due to beer drinking on the part of 
men-when sick they will adhere, when they feel better they 
"forget". 
ART clinic staff, St Luke Mission Hospital 
 
It is likely that alcohol abuse is contributing more to a lack of ART adherence amongst 
male clients than female clients given the cultural context where alcohol consumption is 
more acceptable among males than females. Males intake is also excused because it is 
perceived as a pass time activity. The researcher did not, however, have sufficient time 
and resources to explore this further to determine its validity and reasons behind the 
trend. 
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4.5.5. Non - disclosure of HIV status to partners or spouses 
Disclosure of HIV status to one’s partner and issues of adherence were also brought up in 
the FGDs with PLHIV and treatment supporters. Although this was not highlighted as 
something that any PLHIV in the Rufunsa or Chimusanya support groups had personally 
experienced, it was something they heard was happening with PLHIV in the community.  
Treatment supporters also cited betrothal as a contributor to lack of adherence.  
Specifically, it was suggested that people about to marry stopped taking their medicine 
because they did not want their partners to know they were HIV positive and disclosure 
of their HIV status might result in rejection. As a treatment supporter in Chimusanya 
village stated: 
…When people want to get married, some people stop [taking their 
medicine] because they have met someone to marry and they do 
not want them to know their status. 
Treatment supporter, FGD in Chimusanya 
 
4.5.6. Perceptions on the impact of ART on sexual desire and women’s 
ability to conceive 
The FGDs with support group members in Rufunsa village noted several commonly held 
beliefs about ARVs amongst community members and PLHIVs that reduced adherence. 
For example, a male PLHIV in the FGDs said he believed ARVs “made one loose,” 
because they increased  one’s desire for sex. When probed further, PLHIV in the support 
group seemed to agree and giggled when the comment was made. This appeared to be an 
issue that was accepted and believed to be true among the PLHIV generally - amongst the 
FGD participants  
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Another interesting point expressed during the interviews with health workers was that 
husbands discouraged wives from taking medicine, in particular ARVs because it was 
believed that women on ARVs would not be able to conceive. It would have been 
interesting to explore this further with the females in the support groups.   
 
4.5.7. Religious beliefs as a barrier to taking ARVs consistently  
Religious beliefs are central in shaping lives and behavior in many communities in 
Zambia. The beliefs affect ART treatment as well. Although issues of faith or one’s 
religious beliefs were not particularly highlighted during the in-depth interviews, the 
perceived association between ARV treatment and Satanism was strongly brought out in 
both FGDs. A treatment supporter from Chimusanya village reported that it was common 
knowledge that there was a tendency among pastors in Pentecostal communities to stop 
PLHIV from taking HIV medication: 
One of my clients, a female PHIV stopped taking drugs due 
to religious beliefs and she said that their church pastor has 
urged the PLHIV to stop taking the drugs. A lthough we all 
know that she stopped due to church reasons, she won’t 
accept [that this is true], but she has now defaulted and is 
not taking any medications.  
Female Treatment supporter, FGD in Chimunsanya 
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The PLHIV from one of the support groups in particular stated in the discussion that 
some churches were using the Bible to discourage people from taking drugs. A FGD 
participant in Rufunsa had this to say:  
…I am taking ARVs and the [people from the church] believe that 
they [ARVs] are Satanic. I do not know whether [it is] because 
they talk to God [but] people stop taking drugs. [As a result] some 
have died and others are now sick. 
        FGD participant Refusna support group   
This statement by treatment supporters and PLHIV was collaborated by a health during 
the interviews with informants who had the following to say: 
…Church pastors are preaching about God healing. PLHIV are 
therefore neglecting their medication... 
ART clinic staff, St Luke Mission Hospital 
 
4.5.8. Inadequate food and nutritional support to help adherence to ART  
Lack of adequate food was cited as a key factor in contributing to non-adherence among 
PLHIV on treatment.. PLHIVs, the FGDs in Rufunsa and Chimunsya and three health 
workers all indicated that people in the community stopped taking drugs because the 
drugs made them very hungry.  
 
4.5.9. Forgetfulness and being busy as barriers to adherence 
Whilst in discussion with key informants, it was suggested by one health worker that 
forgetfulness and busyness hindered adherence to medication,  however, these issues 
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were not raised in either the in-depth interviews with PLHIV or the FGDs with the 
support groups of PLHIV or by the treatment supporters. 
 
4.6. Facilitating factors that they have either experienced or anticipate 
will affect the level of ART adherence 
From the in-depth interviews with PLHIV on ART, the FGDs with members of the two 
support groups of PLHIV (most of who were on ART) and the interviews with treatment 
supporters, several themes emerged as adherence facilitators among PLHIV in this rural 
setting. The facilitating factors identified included the following: 
 
4.6.1. Better health resulting from taking ARVs 
Interviewees acknowledged they had been very ill prior to ART. They said they felt much 
stronger and were more productive after starting ART treatment. They were also able to 
engage in more physically demanding tasks such as gardening. Interviewees specifically 
said that ARVs gave them “energy” and improved their physical health and general well 
being. The health improvements experienced were reported as a factor that encouraged 
PLHIVs to continue with treatment. Additionally, interviewees indicated that ARVs 
prolonged their lives. This motivated the interviewees to continue with ART treatment as 
it accorded them the opportunity to live and care for their children. A male PLHIV 
interviewee said the following regarding this during an in-depth interview: 
…I was weak, now I am strong like other people that are not getting 
sick. I am now able to do especially the jobs that I would not manage, 
for example carrying heavy loads. I was unable to walk long distances, 
as I got very tired quickly. Now I am able to walk. 
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Male PLHIV, interviewee # 2  
Another male PLHIV said   
 ...I now have energy or strength to perform a lot of tasks such as 
gardening and working in small fields that do not require a lot of 
strength. I can now also do some piecework that assists me with 
raising resources to meet the needs of my family. 
Male PLHIV, interview # 5 
 
4.6.2. Knowledge of ARVs and belief in the potency of ARVs 
A PLHIV’s knowledge of what ARVs can do and belief in their potency was noted as a 
factor that facilitates adherence to treatment. The support group of PLHIV and the four 
health workers interviewed identified knowledge of ARVs and what the ARVs were able 
to do as factors encouraging patients to continue with ARVs.  
 
FGD participants in Rufunsa emphasized the role confidence in the effects of ARVs had 
in supporting adherence, as recorded from a FGD participant below:  
…. If you believe that these work for [your] life, you go continue 
taking the drugs. ARV is like a "pillow", it's a place of rest. We 
also call the ARVs the headman, if you throw away the ARVs or 
the headman then the whole village is lost. 
FGD participant, Rufunsa support group 
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… I know my status so I take my medicine so that the virus should 
not be strong. I know that the only drugs that can help me is the 
ARVs. I know that I am sick and I need to ensure that I am 
healthy. So I take my drugs so that I do not go back to bed…   
FGD participant, Rufunsa support group 
 
4.6.3. Getting into a regular routine of taking ARVs    
Becoming used to the routine of taking ARVs and other drugs at stipulated times in a day 
were also identified as facilitating adherence. A PLHIV pointed out, during in-depth 
interviews, that the habit of taking the drugs at a specific time had assisted him adhere to 
ARVs.  
…After it was explained to me how to take the drugs, I committed 
to taking the drugs at the right time. I am now used to it. It is a 
daily routine. I understand the value of treatment and I have seen 
what has changed in my body. I am scared if you do not take the 
drugs, I might go back to the old point where I was so sick. I am 
used to waking up at 05:00hrs. I take [the medicine] at 6:00 AM 
the routine is in my head; I just know that it's time to take my 
medicines. 
Male PLHIV, interviewee # 2 
 
This was supported in a FGD with a support group, where a female PLHIV participant 
stated: 
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.... It is now routine. Y ou know that you need to take the 
drugs in the evening when you are cooking nshima [pap or 
porridge]. Y ou know that it is time. 
                           Female PLHIV, support group member, FGD 
 
4.6.4. Disclosure of HIV status and access to social support 
Interviewees were asked if they had disclosed their HIV status to family or any close 
friends, and whether this helped or deterred intake of ARVs. All the interviewees 
indicated that they had disclosed to someone such as a spouse, other family members and 
friends. The social support structure PLHIV identified included family members, friends 
and PLHIV support groups.  Family members such as spouses, parents and children were 
identified as helping PLHIV remember to take their medicine. Disclosure to family, 
therefore, assisted in creating an environment conducive to taking the ARVs. One male 
PLHIV pointed out when asked if he had disclosed his status:  
…Y es, wife knows, my sister. My wife knows that I am taking 
drugs, my sister knows. My wife assists…if I am going far away 
she reminds me to carry my medicines so that I can take them 
any time. Disclosing has made it easier to take my drugs. 
Male PLHIV, interviewee # 2. 
Another participant during the FGDs had the following to say  
Being open, our families remind us to take the medicine especially 
grandchildren. They tell you “grand mother it's now 8:00 hours take 
your medicines”. Being in a support groups also helps. We share the 
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challenges in the groups. This removes fear. If I have a problem I go 
to my friends to get support. 
      FGD participant, Rufunsa support group  
 
4.6.5. Adoption and implementation of strategies to support ARV adherence  
There was general agreement among interviewees and support group members that they 
used many strategies to help them take their medicine regularly and on time, including 
the use of clocks, wrist watches, alarms, cell phones and radios. An interesting strategy a 
FGD participant disclosed was linked to farming seasons, where medicine intake was 
linked to the time they were preparing to go out to the fields. Another female said she 
based the time she took medicine on the cockerel’s behavior. She had the following to 
say: 
…We use cell phones to remind ourselves. We also use the chicken 
crowing. For example, chickens get in their "house"[chicken pen] at 
a particular time in the evening and get out at a particular time in the 
morning. So based on the chicken's behaviour I know that it's about 
time for my medicine. 
Female PLHIV, FDG, Rufunsa support group 
 
During the FGD, another PLHIV had the following to say about strategies to help him 
adhere to medication: 
… We also use clocks and “disco” [digital] wristwatch to help 
 us remember the time to take our medication.  
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      FGD participant, Rufunsa support group  
 
4.6.6. Availability of and access to treatment supporters and ART Mobile  
The in-depth interviews and FGD with support groups  of PLHIV emphasized the role of 
treatment supporters in helping ART patients adhere to treatment. Treatment supporters 
encouraged and advised PLHIV to take their medicine during home visitations with 
PLHIV. Treatment supporters also helped patients correctly count drugs they were 
taking, followed up on appointments and referred PLHIV for medical attention. This 
reinforced adherence support for PLHIV in the community during treatment. A health 
worker also emphasized the important role trained treatment supporters who paid weekly 
visits to patients had in sustaining adherence.  
 
PLHIV in the community not only had access to the treatment supporters, but it was 
highlighted by key informants that the ART facility has initiated an outreach programme 
(ART mobile clinic) that visited the seven villages once a month.   This had contributed 
to ART patients adhering to treatment as services were brought much nearer to PLHIV in 
communities. 
 
4.6.7. Availability of and access to food and nutritional support 
As seen earlier, inadequacy of food and additional nutritional support presented itself as a 
barrier to adherence to ART. The opposite on the other hand served as an ART adherence 
facilitator. Interviewees and members of the support group in the FGD cited availability 
of food and access to nutritional support as a key factor in supporting treatment. PLHIV 
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pointed out, as seen above, that medication increased their appetite. Most PLHIV, 
therefore, needed food and food supplements to make the intake of ARVs effective. 
PLHIV acknowledged the role of food support from the ART facility in enabling and 
motivating adherence to treatment.   
 
The support with food that PLHIV received was in the form of food parcels, which 
included mealie meal, sugar and cooking oil. The ART health facility provided food 
parcels as part of the ART programme, in addition to its key responsibilities including 
community and home based care. However, PLHIV that participated in the in–depth 
interviews and during the FGDs indicated that the food distributed was insufficient and 
suggested the programme increase the quantities of food given to people on ART. 
 
4.7. Health systems challenges and suggestions from health workers to 
supporting adherence to ART among PLHIVs 
The health care workers outlined several health systems challenges they felt contributed 
to PLHIVs reducing adherence to medication in rural areas and offered some suggestions 
on how these could be addressed. These challenges and suggestions were: 
• (Long) distances between patients’ homes—the communities—and the health 
center,  
• Shortage of human resources at the health center leading to work overload. This 
negatively affects staff’s ability to spend sufficient time and give quality care to 
clients during counseling. It was suggested by two health workers that the St Luke 
Mission hospital should increase the number of staff and also employ a doctor 
specialized in ART.   
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• Although the health workers in the ART facility have some ART training, they 
felt that there was inadequate follow-up training, resulting in their inability to be 
conversant and up to date with developments and issues relating to ART. The 
health workers suggested they have more access to refresher courses and 
workshops. 
• Although the ART facility had a mobile clinic which visited the villages once a 
month, the health workers indicated that there was insufficient transport to enable 
staff and treatment supporters access to hard-to-reach patients in communities.  
Increasing transport and the number of bicycles for treatment support would assist 
in this. 
 
A health worker cited the shortage of human resources and consequent work overload on 
staff at the health center as a challenge.Shortages of specialized staff implied that the 
level of work  and the number of tasks allocated to each serving member of the health 
staff increased and kept on changing. . This in turn had a negative bearing on staff’s 
ability to attend to their prescribed duty of counseling and caring for ART patients.  
 
Although PLHIV during in-depth interviews did not cite any specific health systems 
factors as  affecting their ability to adhere to treatment, participants in FGDs with support 
groups members in Rufunsa pointed out that they spent long hours at the community 
health centers (in the villages) and the main hospital. The reason for this was there were 
not enough key health staff such as doctors and nurses to provide support at the health 
center although these were not given as health systems factors.  
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4.8. Suggestions from PLHIV on ART, and treatment supporters for 
supporting PLHIV adherence to medication 
St Luke mission hospital has been implementing the ART programme since 2004. The in-
depth interviews and FGDs support group members and treatment supporters brought out 
several suggestions on how the ART facility could help improve adherence to treatment. 
The following were recommendations for supporting ART adherence in rural areas: 
4.8.1. Access to Income generative Activities (IGAs) and seed packs to 
support farming 
When asked during in-depth interviews PLHIV highlighted the need to have access to 
income generating activities such as poultry to enable theme have income. As most of 
them were involved in farming, they also indicated that provision of seeds to support 
their vegetable gardens and farming would be helpful in making PLHIV stick to their 
treatment. Two PLHIV had the following to say: 
…like we do gardening, may be we can be supported with 
seed for farming 
                       Male PLHIV interviewee, # 2 
Money is needed for example, support groups need money for  
IGAs such as poultry, if one gets sick, you can use the money  
for things that are needed. 
                      Male PLHIV interviewee # 7 
 
Participants during the FGDs with support group of PLHIV were also of the same of 
view and summarized it as follows: 
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We need to increase our incomes, fertilizer is very difficult 
[to access] we need support to increase food production to 
have more food and IGA such as poultry and piggery to use 
for our children and ourselves 
FGD, participants, Rufunsa Village 
 
4.8.2. Sustained nutritional support for PLHIV on ART 
Three PLHIV during in-depth interviews highlighted the need to have access to more 
food. One PLHIV in particular indicated that food should be increased during the periods 
in the year when there was less food.  She had the following to say: 
Food is not usually enough, so we need more food 
especially during the [dry seasons of farming] 
Female PLHIV interviewee, # 8 
 
Participants in the FGDs with support groups of PLHIV also had a similar view. Hunger 
and the need for adequate food had an impact on adherence to ARVs. The ART facility 
gave PLHIV food rations including a packet of 1 kg sugar, a bottle of cooking oil 
(750ml), high-energy protein supplements (HEPS) and a bag of mealie–meal (10kg). This 
package was, however, rationed out for a month only. Participants in the FGD with 
support of group of PLHIV in Refunsa suggested that the duration for which the food 
ration was provided be increased from one month to three. Most PLHIV tend to be too 
sick to work and be self-sustainable when initiating treatment. Increasing the number of 
months from one to three would help PLHIV adhere to treatment.  
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4.8.3. Support and increased emphasis on education and counseling on the 
importance of HIV status disclosure to partners 
Treatment supporters suggested that the ART facility should encourage partners to 
disclose their HIV status to one another. Women should especially be encouraged to 
disclose their HIV status to their male partners since they were more likely to discover 
their status because they are usually tested for HIV during pregnancy. Treatment 
supporters suggested that the ART facility should not only emphasize but also provide 
and encourage clients to attend couple counseling to enable people to disclose their status 
to their partners.  
 
4.8.4. Necessary equipment and training for treatment supporters 
In the FGDs with treatment supporters, they indicated that they worked for no pay in 
most communities. The treatment supporters indicated that they sometimes received 
some incentives provided by the ART facility, which included an allowance of K100, 
00010 and food parcels, which were not sustainable. In addition, most of these treatment 
supporters indicated that they faced many challenges such as walking long distances to 
attend to patients. The treatment supporters also lack home-based care kits, which are 
essential to providing quality care and support for the communities. To be effective in 
supporting ART adherence, Treatment supporters said they needed bicycles for transport 
and to access distant and remote places, umbrellas and gumboots to use during the rainy 
season.   
 
                                                 
10 K100, 000 is equivalent to $ 21.00. Source: The Zambia Daily Mail, Tuesday, October 26, 2010. 
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4.8.5. Increase in the number of treatment supporters and Training for 
treatment supporters 
To support adherence to ART, PLHIV during the in-depth interviewees were of the view 
that the ART facility should increase the number of treatment supporters so they can visit 
and support more PLHIV in the villages. Participants in the FGDs with support groups of 
PLHIV indicated that more people who are on ART should be used as treatments 
supporters as they would be able to teach and encourage others from their experience of 
being on ART. Ongoing training for treatment supporters was cited as important. 
Training would ensure that treatment supporters had the most up to date information to 
provide the necessary support to PLHIV and affected families in the communities and at 
household level. 
 
4.8.6. Increasing awareness of the importance of adherence to ARVs among 
community leaders 
Participants in the FGDs with support groups of PLHIV and treatment supporters 
identified the involvement by key community leaders as essential to addressing 
adherence in the communities. Community leaders are custodians of local culture and 
help influence behaviour in communities. The participants in the both FGDs suggested 
that it would be important to work with village ‘headmen’ and ‘church leaders’ to address 
such issues of ART and adherence.  
The Health facility should work with the church leaders 
and headmen to address the issues of the churches stopping 
people from taking medicine 
 Treatment supporters, FGD inChimunsanya village 
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Community leaders’ involvement would entail training the local leadership in order to 
increase their knowledge and awareness of HIV, ARVs and ART adherence issues.  
 
4.9. Summary: Facilitators and the Challenges of adhering to ART in 
Chongwe District 
Several themes on barriers and facilitators to adherence emerged from the interviews and 
focus group discussions held in three villages in Chongwe district. Barriers to adherence 
included factors related to (a) the client and their religious beliefs, their perceptions and 
knowledge of ARVs, and their abuse of alcohol; (b) therapeutic factors such as the side 
effects of the medication; and (c) socio –economic factors such as stigma and 
discrimination, and fear of rejection from partners resulting in non disclosure of HIV 
positive status.   
 
The facilitators to adherence included access to food to support ART intake, the 
availability of social support from family members and friends, feeling well, being able 
to lead a productive life, getting into a routine of taking medication, knowledge and belief 
in the efficacy of ARVs, use of treatment supporters and provision of mobile ART 
services.  
 
Several suggestions were made that could improve adherence support including access to 
IGAs and seed packs to PLHIV on treatment, sustaining nutritional support for PLHIV, 
increasing the number of treatment supporters and training them, providing bicycles to 
treatment supporters, working with community leaders such headmen and pastors and 
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health care workers, accessing refreshers courses and workshops in ART management 
and delivery. 
 
The next chapter focuses on discussing and interpreting the research findings. 
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CHAPTER FIVE 
DISCUSSION 
 
5. Introduction 
The study set to find out the barriers and facilitators to ARV medication among PLHIV 
in rural areas and specifically, in Chongwe district in Zambia. A range of factors related 
to the barriers and facilitators to adherence were identified through in-depth interviews 
with nine (five women and four men) PLHIV and three FGDs, two with members of 
support groups of PLHIV (23 PLHIV in total) and one with nine treatment supporters. In 
addition, interviews were also held with five key informants who worked at the ART 
facility at St Luke Mission Hospital.  
 
FGDs were held with two functioning PLHIV support groups from two different villages 
served by the ART facility.  FGDs were held to validate the findings from the nine in-
depth interviews. Interestingly, the researcher observed that it was seemingly much easier 
for the PLHIV participants in the FDGs, as they reflected on their own experiences, to 
identify facilitating factors rather than barriers that contributed to adherence.  
Interestingly, as members of a PLHIV support group the PLHIV tended to associate 
PLHIV that were not part of any support group as being the ones who were more likely to 
experience barriers.  On the other hand, PLHIV during the in-depth interviews tended to 
refer to themselves and their own experience in relation to facilitators and barriers.  
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Not surprisingly, the study has shown that there are many factors that are similar to urban 
settings that impact on ART adherence among PLHIV living in rural settings. The factors 
identified can either be categorized into barriers or facilitators to adherence. The 
following were the specific issues that either were barriers or facilitators to adherence: 
 
5.1.1. Acceptance of one’s HIV status and belief in the efficacy of the ARVs 
It was clear from the interviews that the acceptance of one’s status and belief in the 
efficacy of ARVs contributed to PLHIV’s ability or inability to adhere to treatment. ART 
users who had accepted that they were HIV positive and understood that treatment could 
assist in prolonging their lives were more likely to adhere than those that lived in denial. 
This was evidenced in a FGD with a support group of PLHIV in Rufunsa village, where 
participants agreed that PLHIV who denied having HIV usually refused to take their 
drugs. The participants in the discussion indicated that, because they knew ARVs were 
the only medication that could keep them strong and healthy, this motivated them to 
continue to take their medication. This finding has been supported by several research 
studies indicating a strong association between the acceptance of one’s status and belief 
in the efficacy of the treatment (Sidat et al. 2007; Dahal et al. 2008).  
 
Interestingly, despite indicating an understanding of the potential of ARVs to prolong 
life, some interviewees in the in-depth interviews did not yet grasp the implication of 
interrupting doses. This finding is similar with a qualitative study conducted in 
Massachusetts by Law et al. (2005), which indicated that although most interviewed 
patients (84%) on ARV medication reported non-adherent behavior such as interrupting 
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doses,  “holidays” and as forgetting doses, most did not consider their behaviour as being 
non adherent. Only a few in this study were reported to have understood the possible 
consequences of interrupting doses (Law et al. 2005).  Chesney (2004) notes that it is not 
only important for individuals to understand the consequences of non-adherence, 
treatment failure, disease progression and death; but also the challenges that exist when 
treatment failure occurs.  In addition, PLHIV on treatment need to be aware of the lack of 
treatment options available when drug resistance develops.  Community consultations on 
experiences in HIV and AIDS related treatment in urban and rural settings in Zambia 
(International HIV and AIDS Alliance, 2004) found that people in rural settings often 
lacked basic information about HIV and AIDS. A clear understanding of what happens 
when one misses doses both before initiating ART (pre ART) and during ART is thus 
crucial in motivating PLHIV to continue their treatment.   
 
The new ART protocols on Antiretroviral Therapy for Chronic HIV infection in Adults 
and Adolescents in Zambia has indicated that “not skipping doses or stating and stopping 
therapy” are a good measure of adherence (MOH, 2007:15). Whilst the ART facility at St 
Luke Mission hospital does provide adherence counseling during pre ART stage and 
provides follow up adherence counseling when PLHIV are on ART, the lack of 
understanding about the importance of not skipping doses on the part of some 
interviewees on ART suggests the current counseling might need to be reviewed in order 
to address this.  
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5.1.2. The importance of addressing perceptions of impact of ART on sex 
and women conceiving at both individual and community level 
The finding from this study also suggests that there were several commonly held beliefs 
and perceptions about ARVs that are contributing to non-adherence among PLHIV. 
These perceptions included the belief amongst PHLIVs that ARVs made PLHIV “loose” 
and want more sex. Another perception was that women on ARVs would be unable to 
conceive. FGD participants and one of the health workers suggested that husbands 
stopped their wives from taking ARVs as a consequence of this perception. These 
findings suggest that there is still a need for more education about ARVs (and specifically 
what they do and do not do) amongst PLHIVs and the broader community who provide 
support to PLHIV. In addition, within the existing couple counseling being provided at 
the ART facility, it would be useful for the ART facility to look at how to support the 
female PLHIV to be adhere and take their right to treatment.   
 
5.1.3. The role of food and nutritional support in facilitating adherence 
The findings from this study indicated that food is crucial to support the intake of ART 
and therefore, in supporting adherence in rural communities. This has been 
acknowledged to be of importance particularly in rural settings by International 
HIV/AIDS Alliance (2004: 15) when they noted that, “… in rural areas things taken for 
granted in towns, such as access to food and medical care, are in chronically short supply; 
poverty is particularly deep”. 
 
Some interviewees acknowledged, during the in-depth interviews and in all three FGDs, 
that food was important in ensuring that PLHIV on treatment adhered to it. It was also 
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noted specifically by members of the PLHIV support groups and the treatment supporters 
in the respective FGDs that sometimes PLHIV were not adhering to treatment as a result 
of lack of food. Studies in Botswana, Tanzania and Uganda (WHO, 2006; Weiser et al. 
2003) also highlighted the need for food support to be available to PLHIV especially 
when they are starting to take the drugs.   
 
During in-depth interviews most of the PLHIV and in the FGD with treatment supporters 
it was suggested that the food packages the PLHIV currently receive for one month 
should be increased to three months. The current provision in relation to food support for 
PLHIV on ART as indicated in the Zambia National HIV and AIDS strategic framework 
(2006-2010) states that the “strengthening of nutrition education among PLHIV and 
supporting access to micronutrient supplements and access to nutritious food for PLHIV” 
are some of the core strategies to be used in promoting appropriate nutrition and positive 
living among PLHIV (NAC, 2006: 29). 
 
Weiser et al. (2010), found through open-ended interviews with 47 PLHIV in Uganda 
that food insecurity influenced access to medical care and adherence to ARVs.  Findings 
from in depth interviews during this research indicated that PLHIV were so sick before 
starting ARVs that they were unable to grow food or earn income to buy food.  – The 
provision of food to support the nutritional needs of PLHIV in the short term is therefore 
necessary to encourage ART adherence..  
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During discussions with the support group of PLHIV in Rufunsa, participants 
acknowledged the need to increase individual food production through support with 
fertilizer and income generating activities to enable PLHIV to have adequate food. The 
current national response and guidelines in the Zambia National Strategic HIV and AIDS 
framework to mitigate the socio-economic impacts of HIV, emphasizes the “promotion of 
food security, livelihoods and income generation for PLHIV and their caregivers and 
families” as a key response to address food insecurity (NAC, 2006: 31). In the light of 
this policy, there seems to be a gap between what is happening at the ART facility in 
terms of IGA support for PLHIV and the policy. An emphasis therefore in an ART 
facility based in a rural area should therefore be to link PLHIV and their families to 
sustainable livelihood and economic support programmes.  
 
5.1.4. Alcohol abuse as a key barrier to adherence 
Support group members, treatment supporters and health workers cited alcohol as a key 
barrier to adherence. For example, it was noted by support group members that in their 
experience, PLHIV on ART who abused alcohol were usually unable to stay on treatment 
as they did not remember to take their medicines when drunk. This finding is consistent 
with other studies, which have indicated that the abuse of substances such as alcohol and 
the use of active drugs resulted in PLHIV not adhering to medication (Chesney, 2000; 
Power et al. 2003; Methta et al.1997; Dahab et al. 2008).  
 
The key informants, specifically the health workers in the study suggested that there 
seemed to be more men than women abusing alcohol and therefore defaulting in terms of 
 
 
 
 
 75 
their treatment. Although the new ART protocols on Antiretroviral Therapy for Chronic 
HIV infection in Adults and Adolescents in Zambia (MOH, 2007:15) is clear on the need 
to “counsel patients to avoid drug abuse and to refrain from excessive alcohol use” there 
was no indication of a specific programme within the community or at the facility that 
addressed the issues of alcohol abuse in relation to ARVs. Given the experience of health 
workers at the ART facility, particular focus ought to be given to men’s vulnerability to 
alcohol abuse. In addition further research would be useful to provide an understanding 
of the specific issues related to alcohol and ART in rural communities.  
 
5.2. Commonly used strategies to support ARV adherence by PLHIV on 
ART 
The study found that PLHIV in a rural study setting adapted similar strategies to support 
them to adhere to ART as to those in urban settings. PLHIV taking part in in-depth 
interviews and in the FGDs highlighted the types of strategies they used to help them take 
their medicine regularly and on time. These included the use of clocks, wristwatches, 
alarms, cell phones and radios. Similarly, an Australian study Sidat et al. (2007) found 
that PLHIV commonly used various strategies such as PLHIV receiving sms messages on 
their mobile phone organized by their care provider, setting up mobile phone alarms or 
table clock alarm and using of pill boxes.  
 
An interesting strategy a PLHIV interviewee disclosed was linked to farming seasons, 
where the PLHIV said their medicine consumption was linked to the time they were 
preparing to go out to the fields which in the rural context is done very early in the 
morning. Another female interviewee said she based the time she took medicine on a 
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cockerel’s behavior. The latter two examples suggest that some PLHIV seemed to 
develop coping mechanisms that were unique to the rural environment. PLHIV seem to 
be using a combination of strategies to enable them remember what time to take their 
medication although it was not possible to determine how reliable some strategies are in 
supporting adherence.  
 
5.3. Disclosure and social support in families, among couples, friends 
and partners 
The findings from this study related to disclosure and social support from families and 
friends is consistent with other research findings on the role of social support in barring 
or facilitating adherence to medication (Weiser et al. 2003; Dahab et al. 2008; Turner, 
2002). PLHIV during in-depth interviews and PLHIV in support groups suggested that 
where they had disclosed to family members and found themselves in a supportive home 
environment  it was easier to take the medicines. For example, most interviewees during 
in-depth interviews indicated that their children, mothers and other family members or 
friends reminded them to take their medicines at the right time. Turner (2002) argues in 
her review of literature in the USA on adherence to antiretroviral therapy that PLHIV 
who have a good support system that includes family, friends, other role models and 
members of the health care team may be more likely motivated to adhere to treatment. 
 
The new ART protocols on Antiretroviral Therapy for Chronic HIV infection in Adults 
and Adolescents developed by MOH in Zambia also indicates that patients should be 
“encouraged to identify treatment supporters such as family members and buddies and to 
include them in counseling, and supporting patients to overcome obstacles such as 
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disclosure (MOH, 2007:15). In addition, the support group for PLHIV was also 
highlighted as being an important mechanism for receiving support: in providing 
information on ART, giving support to one another, and providing a forum to share 
experiences and enabling one to feel accepted. The ART protocol guideline also 
identifies linking patients to support groups as one of the key ways to support adherence 
(MOH, 2007). Cortez et al. (2004) in their research to  provide ART in poor resource 
settings in South Africa cited and recommended that to attain high levels of adherence, 
community based ART initiatives need to have among other things peer support for 
PLHIV through support groups.  
 
However, accessing support from one’s partner and/or family does of course require 
disclosure of one’s HIV positive status.  The FGDs with both PLHIV in support groups 
and treatment supporters revealed that women in particular were perceived to be afraid of 
disclosing their status and use of ARVs to their partners. Treatment supporters in 
particular suggested that the reason for this was that they feared that the disclosure of 
their status would lead to them losing their spouse or partner. For single PLHIV there was 
a fear that disclosing their HIV positive status would mean they would not get married. 
Interviewees thus suggested the fear of rejection within relationships, as a key barrier to 
treatment adherence. Women seem to face negative consequences as a result of their 
disclosure of their HIV status. Kumarasamy et al. (2005) have also indicted the 
complexities of disclosure and its consequences especially for women.  
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In addition, it was suggested by treatment supporters’ that husbands were known to 
discourage their wives from taking ARV because it was believed, among men, that 
women on ARVs could not get pregnant. As mentioned previously there is need to 
correct incorrect beliefs amongst both PLHIV and their support network including 
spouses, family members and the wider community to maximize adherence support.  
 
In looking at gender dimensions to accessing treatment in rural areas, community 
consultations conducted in Zambia by International HIV and AIDS Alliance (2004) on 
experiences of HIV and AIDS related treatment in urban and rural settings found that 
women in general needed much more information and education on HIV and AIDS and 
treatment as they were particularly vulnerable.   
 
5.4. Embarrassment, stigma and discrimination as a barrier to 
adherence 
This study found that embarrassment, stigma and discrimination acted as barriers to 
adherence among PHLIV. It was noted during the FGDs discussions with support groups 
of PLHIV that HIV-related stigma and discrimination was a barrier to adherence among 
PLHIV.  The participants in these FGDs highlighted that they were aware of ART users 
that felt embarrassed and shy about taking medicine in public or to be seen with side 
effects. This contributed to their inability to take their drugs in the presence of other 
people and contributed to their inability to adhere to their treatment  
 
This finding is similar to findings a Zambian urban and rural research study conducted in 
Lusaka, Ndola and four villages in Southern province by the International HIV/AIDS 
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Alliance (2004). The study identified stigma and discrimination as one of the main 
barriers for PLHIV to access treatment or care for fear that their HIV, status is known. 
International HIV/AIDS Alliance (2004) in their study citied “fear and stigma” to be 
“particularly powerful” in the rural areas of southern province in Zambia as these were 
for example, seen to “discourage people from using voluntary counseling and testing 
(VCT) services and made it difficult for people with HIV to be open about their status” 
(International HIV and AIDS Alliance, 2004: 15).  Other studies in developed countries 
have confirmed the finding that stigma and discrimination contributes to non-adherence 
to treatment (Dahab et al. 2008; Kumarasamy et al. 2005; Weiser et al. 2003).  
 
5.5. Religious beliefs and their role in adherence to ART 
An interesting finding in the research was the possible link between faith, healing and 
non-adherence. Treatment supporters, support groups members and health workers all 
noted that some religious groups (such as the Pentecostal churches) served as a major 
barrier to adherence. For example, some pastors were citied as urging PLHIV to stop 
treatment because they had been “healed” by faith and prayers. PLHIV from a support 
group in Rufunsa village cited cases of PLHIV who had died as a result of stopping their 
medication. In addition, one interviewee (# 6 in Table 1) was cited by treatment 
supporters as one of the PLHIV on ARVs that had stopped taking their medication as 
result of a pastor telling her to stop her medication. This finding is consistent with the 
findings in a prospective observational study, conducted in Uganda which found that 
1.2% of patients discontinued ART because of a belief in spiritual healing (Wanyama et 
al. 2005).   
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It is also worth noting that there is a belief on healing of HIV as a result of prayer even 
among people who do not know their status. In an exploratory study conducted in 
Tanzania by Zou et al. (2009) on associations between religious beliefs and HIV stigma, 
disclosure and attitudes towards ARV, the majority of respondents from Catholic, 
Lutheran and Pentecostal churches believed that prayer would cure HIV. However, 
almost all of them indicated that they would begin ARV treatment if they became 
infected (Zou et al. 2009).    
 
As one of the health workers pointed out faith can nonetheless also contribute to helping 
one continue with medication. Churches have traditionally played a key role in 
prevention, treatment care and support programmes in this community in Zambia. For 
example the current ART facility at St Luke Mission hospital is being implemented by 
Catholics nuns.  In addressing adherence, there are opportunities for greater collaboration 
between the ART facility at St Luke Mission Hospitals and religious leaders. In addition, 
through using treatment supporters who are living with HIV, the ART facility can 
advocate for more positive involvement and education amongst religious leaders. 
Wanyama et al. (2005) argue and suggest that spiritual beliefs should be an important 
part of ART adherence counseling in resource-limited settings, requiring close 
collaboration between HIV care programmes and religious leaders to identify common 
goals and ensure successful treatment. 
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5.6. The role of treatment supporters as facilitators to adherence 
The value of using ART treatment supporters has been citied by Nachega et al. (2006) as 
one of key strategies to support adherence of ARVs in communities. Treatment 
supporters and their support to PLHIV on ART is a key facilitator to adherence (Nachega 
et al. (2006).  Findings of this study revealed that treatment supporters were responsible 
for providing adherence counseling, following up clients in their homes, checking clients’ 
pills, making referrals and accompanying clients on their first day of receiving treatment. 
Treatment supporters were also the link between the ART facility and the communities.  
 
However, during the research several challenges were suggested by treatment supporters 
in relation to their service provision and incentives: the need to have access to livelihood 
opportunities as the K100,000 allowance and food parcels treatment supporters receive 
was not adequate and sustainable. There was also the need for supporters to to have 
bicycles to access clients in remote areas and appropriate protective clothing such as 
raincoats and gum boots for the rainy season. It is very likely that responding to these 
basic needs will contribute to making the work of treatment supporters easier and ensure 
that they are adequately motivated.  
 
5.7. The role of ART mobile clinics in facilitating adherence 
Distances to a health facility and costs associated with accessing health facilities have 
been known to impact on adherence to ARVs (Weiser et al. 2003; Kumarasamy et al. 
2005). In this study the issue of costs associated with accessing health facilities was not 
highlighted as a barrier to being adherent. This could be attributed to the fact that the 
ART facility had developed an ART outreach programme to reach communities by using 
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mobile ART clinics. In addition, most of the services provided at the ART facility were 
free. Each village was visited once a month by a team from the St Luke’s Mission 
Hospital’s ART facility. However, it is possible that there are still areas that the outreach 
programme is unable to access as suggested by some key informants, who indicated the 
challenges they faced with transportation and accessing hard to reach areas. 
 
5.8. Addressing health systems challenges to facilitate adherence in 
rural communities 
Strengthened health care systems are important in supporting adherence to medication 
among PLHIV in urban and rural settings in Zambia. However, special focus needs to be 
placed on rural settings as “overall, lack of human resources and infrastructure for HIV 
testing, counseling and treatment are widespread in rural areas” (International HIV and 
AIDS Alliance, 2004:15).  The findings from this study indicated that staff at the health 
facility has several challenges that they believe influence their ability to deliver better 
services to clients. The challenges they specifically cited included inadequate training in 
adherence counseling and support, inadequate transport to access the more distant 
villages, and too few staff available to counsel or attend to patients.  
 
The Health workers in the study acknowledged the need for further training in ART and 
adherence although they felt there were not enough opportunities for access to training. 
The ART Protocols (MOH, 2007) state that one of the requirements for health providers 
is that they participate in continuous medical education in the use and monitoring of 
ART. In addition, the national guidelines on management and care of HIV and AIDS 
(2004:4) emphasize that “to achieve the goals of the health reform programme, health 
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care workers both at institutional and the community level in both public and private 
health sector must be trained in HIV and AIDS management and care”. 
 
Harries et al. (2001) in their paper on provision of ART in Sub Sahara Africa and 
suggestion on a framework for delivering ART in Sub Sahara Africa cite government 
commitment as one of the key elements in provision of nationwide coverage of ART in a 
country. Although policy is in place to support the provision of ART the reality is that 
adequate resources have not been allocated in all countries to support ART roll out. 
Overall the health care system has been over stretched and strained, resulting in poor 
service delivery. It is acknowledged in Zambia that the high prevalence of HIV and AIDS 
related illness has seriously overburdened the health systems in Zambia (NAC, 2004). 
 
5.9. Implications for policy research and practice in rural areas 
This qualitative study was conducted among PLHIV taking ART and living in the rural 
areas of Chongwe district in Zambia. The findings indicated that there were several key 
factors that contribute to the level of adherence among PLHIV in rural areas. Findings 
from this study, highlight the challenges that exist when health facilities are located far 
from the communities they service and the ART facility do not have adequate transport to 
reach hard remote areas. Although St Luke Mission Hospital had outreach centres linked 
to the ART facility, bringing health services closer to communities remains a challenge. 
Distances to health services can therefore be a barrier to adherence. This implies that 
people will often prefer seeking alternative medicines such as traditional healers first, 
because they are closer; and resort to health services last. Although, further research is 
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needed to ascertain if this is the case in Zambia, it was noted that traditional healers are 
more commonly used in rural areas than in urban settings (International HIV and AIDS 
Alliance, 2004).    
 
Evidence from the study suggests that treatment supporters are key facilitators to 
treatment adherence among PLHIV in rural areas.  Treatment supporters are the 
backbone for care and support services in communities and in supporting adherence 
(NAC, 2004). Treatment supporters need be valued and recognized and their work 
adequately resourced by government to support the provision of incentives and 
equipment. Cortez et al. (2004) in the their research in providing ART in poor resource 
settings in South Africa cited and recommend that to attain high levels of adherence, 
community based ART initiatives need to have a strong-patient centered approach, 
comprehensive counseling which includes well trained lay counselors that provide one-
on-one counseling for people taking ART. 
 
Faith plays a key role in shaping of values, beliefs, behaviors and attitudes of people in 
Zambia and the faith community has also played a significant role in the provision of care 
and support for PLHIV in Zambia.  As the findings seem to suggest some PLHIV in the 
rural community are stopping treatment as a result of belief in being healed by faith.  It 
will be important to explore this further to understand this and determine how best to 
work with churches to effectively support and sustain adherence of ART among PLHIV 
in rural communities.   
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As has been suggested elsewhere (Chesney, 2000; Power et al. 2003; Methta et al. 1997; 
Dahab et al. 2008) and in this study, the abuse of alcohol was highlighted as a key barrier 
to adherence especially among men in the community. The link between alcohol and 
ARVs needs to be understood in order to design sustainable approaches to provide 
support to PLHIV and families dealing with alcohol abuse.  
 
Finally, the evidence from the study highlights the need to further address perceptions 
about ARVs at both individual and community level.  The findings underscore the need 
to ensure that programmes at community level are relevant to emerging issues in the 
community and the need to have updated training for treatment supporters, as these are 
key in providing information to individuals and communities.  
 
5.10. Conclusion 
Adherence to ART is complex. The study showed that adherence depended on many 
factors.  For example, at an individual level a belief in the efficacy of treatment and the 
acceptance of one’s HIV positive status acted as facilitators to adherence. At the same 
time believing that one could be healed (from HIV) after receiving prayers acted as a 
barrier to treatment. In addition, the abuse of alcohol, stigma and discrimination, the fear 
of rejection and the perceptions about how ARVs impacting on ones’ ability to give birth 
also acted as key barriers to adherence.   
 
The study illustrated that social support through support groups and family members, the 
provision of food and nutritional support, the use of treatment supporters and mobile 
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ART services acted as facilitators to adherence. As PLHIV live in communities, 
perceptions of community members can act as barrier or facilitator to adherence.   As 
seen from the study, there are some factors that are similar in both urban and rural 
settings. The International HIV/AIDS Alliance cite these as being food insecurity, use of 
traditional healers and stigma Community consultations conducted in both urban and 
rural settings in Zambia by International HIV and AIDS alliance (2004), revealed that 
some factors were particularly significant for rural communities. These included factors 
such as “access to food and medical care, which are in chronically short supply; poverty; 
language problems being complex; traditional healers were commonly used; people often 
lacked even basic information about HIV and AIDS and the fear and stigma are 
particularly powerful in rural communities, Overall, lack of human resources and 
infrastructure for HIV testing, counseling and treatment are widespread in rural areas” 
(International HIV and AIDS Alliance, 2004: 15).  
 
 
 
 
 87 
CHAPTER SIX 
CONCLUSION 
 
6. Introduction 
This study aimed to determine the knowledge, perception and opinions about the 
importance of ART treatment from the perspectives of PLHIV. The study also aimed to 
explore the barriers and facilitators that PLHIV have either experienced or anticipate will 
affect their level of ART adherence. 
 
Through a series of in-depth interviews and focus group discussions with PLHIV and a 
FGD with treatment supporters the study identified several barriers and facilitators to 
ART adherence in PLHIV in rural areas. Reported barriers to adherence among PLHIV in 
rural areas included such things as experiencing side effects as a result of taking ART, 
feeling an improvement in health and thus stopping to take their medication, a lack of 
understanding of the importance of adherence, and the abuse of alcohol which resulted in 
PLHIV forgetting to take their medication. Other barriers included stigma and 
discrimination that impacted on the ability of PLHIV to adhere to treatment, inadequate 
food to support ART uptake, non disclosure of one’s status for fear of being rejected 
especially for women who feared rejection in relationships and negative perceptions 
about the ARVS. Another key barrier to adherence was the religious belief reportedly 
held by some PLHIV that one would get healed after being prayed for and therefore 
treatment was discontinued. 
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Key facilitators to adherence identified in the study included getting into a regular routine 
of taking ARVs, knowledge and belief in the efficacy of ART, disclosure of HIV status 
and access to social support which enabled PLHIV to get support and adhere to 
medication and nutritional support that enabled PLHIV to have access to adequate food 
to support uptake of ART. Other facilitators identified were use of treatment supporters 
who provided support to PLHIV by providing them with on-going adherence counseling, 
and making referrals to the ART facility for further support, mobile ART clinics that 
have brought ART services closer to the rural communities and the adaptation of 
strategies such as clocks and use of alarms by PLHIV to remind them to take their 
medication. Although better health resulting from taking ARVs was citied as a barrier to 
adherence, it also acted as facilitator to adherence as better health motivated PLHIV to 
continue taking their medication. 
 
6.1. Limitations of the study 
The study had several limitations. Firstly, the selected sample of PLHIV interviewees 
from St Luke’s Mission hospital did not include all types of PLHIV groups that might 
have provided a different perspective on barriers and facilitators to adherence. For 
example:  
a) The researcher recruited interviewees from the ‘active’ patient list of the 
hospital. The researcher therefore did not try and recruit those that had completely 
defaulted or stopped taking their medication. 
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b) From the ‘active’ patient list, the researcher was limited in terms of the ability 
to reach everyone on the list because of the season in the year, when the study 
was conducted. As a result, the researcher only interviewed those that were living 
within a distance of 45 minutes to one hour of driving from the ART facility at St. 
Luke Mission hospital. It is worth noting that the mode of transportation in many 
of the villages surrounding the heath facility is either use of bicycles or walking as 
there is no public transportation available. As it was the rainy season, some 
PLHIV could not be accessed as a result of long distances from their homes to the 
health facility and inaccessible roads (e.g. most “hard to reach places” were 
inaccessible due to impassable roads, and therefore no vehicle was able to get to 
the villages). Other villages were not accessible due to the limited time that the 
researcher had, as it would take more that an hour and a half minutes’ drive as 
opposed to the 45 minutes and an hour, respectively the researcher took to drive 
on visits to the two sampled villages. It was not therefore possible to get PLHIV 
that were living further than 45/1hr away from the hospital. 
 
Secondly PLHIV during the in-depth interviews and FGDs may have provided responses 
that were aimed at pleasing or impressing the researcher and of wanting to be perceived 
as a ‘good patient’ and thus only reporting behavior that was perceived to have positive 
consequences. This is considered a possibility given that the researcher was introduced to 
the PLHIVs by one of the health workers from the ART facility at the St Luke Mission 
hospital. In addition, support group members in one of the FGDs tended to refer to 
‘other’ PLHIV (i.e. those who were not part of the support group) and were – it was 
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suggested - more likely to experience barriers to adherence than themselves. By referring 
to others, PLHIV did not then necessarily reflect on and talk about their own direct 
experiences – and the researcher was thus provided at times with information, which 
appeared to be largely hearsay.  
 
6.2. Recommendations 
St Luke Mission Hospital has been providing care and support to PLHIV in the 
community for many years and in 2004, with the establishment of the ART clinic, the 
hospital started to provide ART as part of its range of services. The study looked at 
barriers and facilitators to adherence among PLHIV. Based on the findings of this study, 
it is recommended that it’s ART facility consider in terms of future planning in relation to 
ART adherence among PLHIV: 
 
6.2.1. Addressing alcohol abuse among PLHIV on treatment 
The abuse of alcohol among PLHIV, and especially men, on medication was identified as 
an emerging problem within these rural communities. To support adherence, the new 
ART protocols on Antiretroviral Therapy for Chronic HIV infection in Adults and 
Adolescents developed by MOH in Zambia (MOH, 2007:15) importantly emphasizes the 
need to “counsel patients to avoid drug abuse and support patients to refrain from 
excessive alcohol use”. It also emphasizes the need to “identify ways to assist patients 
overcome obstacles” in relation to treatment and “linking patients to adherence support 
groups” (MOH, 2007:15).  
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As there was no counseling programme that was addressing the issues of alcohol and 
HIV in the community, it will be beneficial for the ART programme to consider 
developing a programme that can address the specific issues related to the use (and 
abuse) of alcohol in the community. In addition, the establishment of a support group 
specifically for those that are on ART and are struggling with the abuse of alcohol would 
be useful to establish in terms of providing additional support to PLHIV that are likely to 
also be struggling with issues related to adherence. Possible collaboration between the 
ART facility at St Luke Mission Hospital and with other agencies and programmes that 
focus on drug and substance abuse (for example, The Anti-Corruption and Drug 
Commission in Zambia should be explored so as take advantage of their experience and 
skill in this area.  
 
6.2.2. Addressing perceptions of ARVs in the community 
A number of incorrect perceptions about ARVS and taking ARVS exist within the rural 
communities where the study was conducted. These perceptions might be acting as 
barriers to adherence. It is thus recommended that the ART facility regularly update both 
the content of their community awareness programmes and their training programmes for 
treatment supporters in order to ensure that some of the negative perceptions held by the 
community about ART be clarified. Community sensitization should specifically 
continue to address issues of disclosure, stigma and discrimination to ensure that PLHIV 
are supported to take their treatment without feeling shy or embarrassed.  
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6.2.3. Review of the counseling programme 
On a number of occasions in the interviews it was noted that women are more likely to 
face negative consequences in disclosing their HIV positive status and thus require 
additional support in relation to disclosure.  It is thus recommended that the ART facility 
at St Luke Mission Hospital consider how best it could offer additional psychosocial 
support to their female clients as they face the significant challenges associated with 
disclosing their status to their male partners, families and friends.   
 
6.2.4. Strengthening of food security and livelihood opportunities for PLHIV 
and their families 
The Zambia National HIV and AIDS Strategic framework (NAC, 2006: 31) identifies the 
“promoting of food security, livelihoods and income generation for PLHIV and their 
caregivers and families” as a key response to support treatment in communities.  The role 
of food in relation to supporting the uptake of ARVs cannot be over emphasized. 
Increasingly programmes need to ensure that PLHIV are not dependent on hand outs and 
food parcels for their living. Emphasis by the ART facility at St Lukes Mission Hospital 
should therefore be placed on making linkages and creating opportunities for PLHIV and 
their families to have access to sustainable food security and livelihood programmes.  For 
example, more formal linkages with the Ministry of Agriculture and NGOs such as 
Programme Against Malnutrition (PAM) could be explored.  
 
6.2.5. Caring for treatment supporters 
Treatment supporters are the back borne of providing care and support at household and 
community level.  It is therefore important for the ART facility at St Lukes Mission 
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Hospital to continuously invest in their treatment supporters. In addressing the challenges 
faced by treatment supporters, the ART facility should explore how it can provide 
treatment supporters with adequate updated training and the tools for their work (such as 
providing them with bicycles and HBC kits).  Treatment supporters should also have 
access to sustainable livelihoods opportunities so that they are less dependent on food 
rations, which are currently being provided as incentives by the ART facility.   
 
6.2.6. Increasing collaborating with churches and traditional leaders 
In order to address the specific challenges of Pentecostal churches discouraging PLHIV 
from taking treatment, the ART facility St Luke Mission Hospital should explore 
opportunities for using the existing NAC structure known as the District AIDS Task 
Force, which is responsible for coordinating HIV and AIDS activities within the district.  
Using this structure, a stakeholders meeting could be held to bring together leaders from 
all faith based organizations and traditional leaders in the community. This meeting could 
look at issues of faith, use of traditional medicines and ART, and possibly identify 
research questions that can be explored further to provide further insights.  
 
It will be important for the ART facility to create a platform where the ART facility, faith 
leaders and traditional leaders can work together to design appropriate strategies to 
respond to existing challenges in the community. This will be in line with the National 
HIV and AIDS strategic framework (May, 2006) that calls for a multi-sectoral response 
to HIV and AIDS as it recognizes that there are various key players in the HIV and AIDS 
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response and therefore the need to work in a more coordinated way to address HIV and 
AIDS in communities. 
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APPENDIX A: Problem Analysis 
 
 
Lack of adherence 
Client/patient factors:  
Patient’s knowledge and 
beliefs about HIV and 
ARVs,  
Negative belief about the 
treatment, 
Psychosocial issues such as 
life stress and depression, 
Substance abuse, 
Forgetfulness 
Socio-economic factors  
such lower income and 
educational levels, costs 
involved in accessing 
treatment, distance to services 
providing the service, Stigma 
and discrimination and lack of 
family support 
Service provider factors 
Inadequate trained Human 
capacity responsible for 
testing, care and treatment 
related care, inadequate 
budgets to procure drugs and 
other related support services 
for ART 
Distance to the ART facility 
 
Service 
provider/patient 
relationship:  
Lack of clear instructions 
from health worker or 
community 
volunteers/treatment 
supporters 
Patient’s overall 
satisfaction and trust in 
the service providers
Therapy –related 
factors: complex 
treatment regimes, Side 
effects as a result of the 
treatment, 
Lack of clear instructions 
about how to take the 
drugs 
Lack of Community 
support through 
stigmatising and 
discriminating those that 
are HIV positive or 
perceived to be HIV 
positive. 
Lack of or 
misinformation 
about HIV, 
treatment and 
adherence 
information  
Figure 1: Problem Analysis 
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APPENDIX B: Work Plan 
Table 2: Work Plan 
Research activities Months 
Year 2008 
May Jun July Aug Sept Oct 
Review of research with ethics committee       
Obtain clearance from the St Luke’s Mission 
hospital 
      
Piloting and finalizing the research instrument       
Data collection       
Data analysis and report writing       
Submission of thesis for comments and reworking       
Submission of draft to St Luke Mission 
Management staff 
      
Finalizing the report and submission to SOPH for 
submission. 
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APPENDIX C: Budget 
 
Table 3: Budget 
Description Unit price 
(Kwacha) 
Number 
of Days 
Number 
of 
Persons/ 
quantity 
Total cost 
(Kwacha) 
1. Stationary 
• Tape recorder and    
tapes 
• Microphones 
• Note books & pens 
 
100,000 
 
50,000 
5,000 
  
1 
 
1 
5 
 
150,000 
 
50,000 
25,000 
2. Pilot study 20,000 2 5 100,000 
3. Allowance for 
participants and snacks 
K30, 000 10 20 600,000 
4. Transcribing K100, 000 5 2 1,000,000 
5. Photocopying of consent 
forms 
500  20 10,000 
6. Data collection 
• Fuel costs 
• Lunch allowance 
 
 
  1,000,000 
7. Photocopying reports 10,000  30 300,000 
8. Dissemination meeting K20, 000 1 30 600,000 
Sub total    3,835,000 
5 % contingency    191,750 
Grand total    K4, 
026,750 
Grand total in $    $1,060 
Budget notes 
• Participating clients in depth interviews (3) will be provided with an allowance to provide 
transport reimbursements 
• Two typists (4) will be hired to assist with transcribing from the record tapes. 
• Dissemination meeting (8) will be used to present findings to staff of St Luke Mission 
Hospital and other stakeholders 
• Due to do unforeseen circumstances, a 5% contingency has been added to the cost to cushion 
any unforeseen circumstances  
• Current exchange rate is approximately K3, 800 to a dollar. 
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APPENDIX D: In - depth Interview Guide with PLHIV on ART
11 
 
Greetings (Good morning or afternoon), my name is Charity Sisya and I am a student of 
Public Health with the University of Western Cape, in South Africa. Thanks for giving 
me this opportunity to meet with you. I am interested in asking you a few questions that 
will assist me to identify the possible barriers and facilitators that might affect the level of 
ART adherence among people living with HIV/AIDS in rural communities. The 
information I obtain in this interview and other interviews like this will hopefully be used 
to support the further development of strategies to support ART adherence in rural areas.  
 
Here is an information sheet about the research I am conducting. We can read it together 
- and I can answer any questions that you might have. 
Note: Refer to the participant information sheet, read it in the local language for 
those that cannot read. Give an opportunity for questions.  
I just want to re-emphasize that if you would prefer NOT to take part in this research 
study it will not affect you in anyway – and particularly not in terms of the quality of 
support that you receive from the ART clinic. 
Note: Once it established that the person has no further questions, then ask the 
following: 
I would like to know if you are willing to participate in this interview?  
If the potential participant says NO:  
Thank you very much for taking the time to listen to me, I wish you the best.  
 
                                                 
11 The questionnaire was adapted from the International HIV/AIDS Alliance study of the experiences of 
treatment users and health care workers, 2004 and WHO research From access to adherence: the 
challenges of antiretroviral treatment, studies from Bostwana, Tanzania and Uganda, July 2006. 
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If the potential participant has agreed to be interviewed, then proceed 
with the following: 
Thank you again for accepting to be interviewed.  This interview will take only about 1 to 
2 hours. But before we start the interview, I would like us to go through the informed 
consent form (the consent form to be read in the preferred language of the participant),  
Note: emphasize the following   
• The interview process (i.e. what it will involve) 
• The participate can with draw at any stage or chose not to answer any questions 
that makes them uncomfortable 
• Issues of confidentiality 
• Explain why I want to use a tape recorder – and request permission to do so. 
Ensure that the consent form is signed by both participant, or consent is given on tape and 
the person conducting the research. 
 
Thank you again, I just want to assure you that everything discussed here will be used 
solely for the purpose of my studies and the overall findings (from all the interviews I 
conduct) will be reported back to St Luke Mission Hospital. Your name will not however 
ever be included in the research report or referred to during the report back process. 
 
First I would like to find out some background information about you: 
 
1. Demographic information 
1.1 Sex (to be noted by the interviewer)  
1.2 What is your marital status (Probe if married, single, divorced, widow, widower 
and cohabiting)?  
1.3 How old are you? 
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1.4 What level of education have you attained? (None, primary, secondary) 
1.5 What do you do for a living? 
1.6 Do you belong to a support group for people living with HIV? 
1.7 How do you travel to the ART clinic? Probe (taxi, bus, walk)?  How long does it 
generally take you to get to the clinic?   
2. Knowledge and perceptions about ARV treatment 
2.1 I would like to understand what you know about ARVs.  Can you explain to me 
what the purpose  of taking ARVs is?  
(Probes: what are they meant to do in relation to your health? What is their 
expected benefit?) 
2.2 What particular ARVs are you taking  at the moment?   
(Probes: do you know the names of the ARVs you are taking – or if not, what do 
they look like) 
2.3    What do you understand that you have to do in terms of taking  the medication 
for it to be effective?  
(Probes: How long do you have to take them for?  How often do you have to take 
them? In what combination?) 
2.4      Before starting on ARVs where did you get information about ARVs?  
(Probe: Reading materials such as posters, books; friends; the HIV support group, 
HBC, through the counselor at the health facility, church, medical personnel, 
other sources – and if so, ask them to specify) 
3. ARVs and adherence to treatment  
3.1 How long have you have been on ARV treatment? 
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3.2 Besides ARVs are there other medications you are taking?  For what? When did 
you start taking this medication? When do you have to take this medication 
(Probe: daily basis or not? Forever or not?)  
3.3 People have various experiences with ART – some of them good and others not 
so good. Can you explain to me your experience of being on ART.  Lets first 
focus on the positive experiences  you have had.  Can you tell me what some 
of your positive experiences have been in starting ART (in other words the 
positive changes that you have experienced)? 
(Probe: difference made to their physical health, and mental health/sense of general 
well being, difference in terms of primary relationship (e.g. partner)) 
3.4 Now lest focus on the negative or difficult experiences  – what have you 
found to be difficult or a challenge about starting and now being on ART? 
(Probe: experiences of stigma associated with taking ART, experience of side effects, 
difficulties in accessing the drugs, difficulties in having to take them, their lack of 
knowledge about things that come up and they don’t know what to do, lack of food to 
support ART up take, lack of money, distances to the clinic,)? 
I am particularly interested in looking at some of the ways ART 
patients are dealing with having to take medication each day.  As I 
had said earlier at the beginning of our discussion, what ever you say 
to me is anonymous, your name is not being recorded – so I hope that 
you feel comfortable enough to share with me some of your real 
experiences – The information you are sharing with me will be used 
to help gather information that can help others on ART adhere to 
their treatment particularly in rural areas.    
3.5 Have you perhaps missed a dose in the last day, 4 days, one-week or month?  
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This is a very important question. I appreciate how difficult it is to take medicines 
daily. If you do miss a dose, please can tell me the reasons for missing the doses? 
Please give me an example or two 
Probes: simply forgot, lack of food, use of alcohol, feeling better or well, busy 
doing other things, being away from the place of residence, distance to the health 
facility, fear of stigma and discrimination, depressed, experiencing side effects, 
waiting times at the clinic, drugs have finished or any other reasons, 
3.6 What do you think happens in your body if you skip or forget to take your ARVs  
3.7 Lets now talk about the things that help you take your pills  regularly and on 
time? 
Probes:  (e.g. buddy, relatives, clock, cell phone, children, acceptance of the HIV 
status, disclosure, beliefs about the value of treatment, feeling better and others)?  
3.8 Have you disclosed your HIV + status to someone close to you (like your 
partner, someone in your family, your close friend)?  
(Probes:  
DISCLOSED: Who have you disclosed to? Do they know that you are on ARVs?  
And if so, do they help you to take your pills?  Does this help you or make things 
more difficult in terms of taking your pills? 
NOT DISCLOSED: How does this affect you taking your pills? 
4. Discussing ARVs and adherence with the clinic staff  
4.1       What would you do if you were feeling sick after taking your medications?  
(Probe: would you tell your doctor or nurse? When would you tell them (at next 
clinic visit, go especially to the clinic) 
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4.2      What would you do if you have forgotten to take your medication over the last 
period   from one clinic visit to the next?  
(Probe: would you tell your doctor or nurse? why is this so?) 
4.3 With your experience of taking ARVs, what would you tell someone as the most 
important things they need to know to help them take their pills every day? 
4.4 If the clinic asked you how you think they and their staff could offer 100% support 
and information to keep ART patients adherent - what would you tell them? 
4.5 What type of support do you think the support groups of PLHIV need for them to 
be most helpful for people taking ARVs to help them stick to their treatment?  
5.  Cost Considerations 
5.1       How much do you have to pay to cover your travel expenses every time you visit    
the clinic?  
5.2        Do you incur any other costs as a result of taking ARVs? (Probes: increasing 
food costs, costs associated with tests at the facility, reduced income due to side 
effects)  
5.3        Do you lose income as a result of your coming to the clinic for reviews or 
refills? 
I would like to thank you for taking time to answer to my questions. As I 
had mentioned at the beginning of the interview, I would like to re-assure 
you again that whatever we have discussed here will be solely for the 
purpose of fulfilling my studies and help develop strategies that can 
support ART adherence in the rural areas. The information provided will 
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be treated with strict confidence and your name will be not included in 
the report or other interviews. 
 
Do you have any questions that you would like to ask me - or would you like to tell me 
anything else?  
I would like to thank you again for your time and the information that you 
have shared with me and I wish you the best.  
Note: if issues of further referral have been identified during the interview then refer 
participant to the relevant support structures within the health facility 
 
END OF INTERVIEW 
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APPENDIX E: Interview Guide for Health Workers at the ART facility 
 
Greetings (Good morning or afternoon), My name is Charity Sisya and I am a student of 
Public Health with the University of Western Cape, in South Africa. Thanks for giving 
me this opportunity to meet with you. I am interested in asking you a few questions, that 
will assist me to identify the possible barriers and facilitators that might affect the level of 
ART adherence among people living with HIV/AIDS in rural communities. The 
information obtained in this interview and other interviews like this will be used to 
support the further development of strategies to support ART adherence in rural areas.  
 
Here is an information sheet about the research I am conducting. We can read it together 
and I can answer any questions that you might have. 
 
Note: Refer to the participant information sheet. Give an opportunity for questions. 
Once it established that the person has no further questions, then ask the following 
 
I would like to know if you are willing to participate in this interview?  
 
If the potential participant says NO: Thank you very much for taking the time to 
listen to me, I wish you the best.  
If the potential participant has agreed to be interviewed, then proceed with the following: 
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Thank you again for accepting to be interviewed.  This interview will take only about 30 
minutes to 1 hour. But before we start the interview, I would like us to go through the 
informed consent form, (Give the participant the consent form and read it with them) 
emphasizing the following  
• the interview process (i.e. what it will involve), 
• The participate can with draw at any stage or chose not to answer any questions 
that makes them uncomfortable 
• Issues of confidentiality,  
• Explain why I want to use a tape recorder and request permission to do.  
Ensure that the consent form is signed by each participant, or consent is given on tape 
and the person conducting the research. 
 
Thank you again, I just want to assure you that everything discussed here will be used 
solely for the purpose of my studies and overall the findings from all the interviews I 
conduct will be reported back to the St Luke Mission Hospital. Your name will not 
however be included in the research report or referred to during the reportback process. 
 
First I would like to get some back ground information from you 
 
1. Background information 
1.1 What is your role in the ARV programme at St Luke Mission Hospital? 
1.2 What is your Profession? 
1.3 How long have you been involved or working in the area of HIV/ART 
related health care delivery , 
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1.4 How long have you been working  in particular this facility?  
2. Training 
2.1 What specific training have you received for this job in relation to the ARV 
programme: can you tell me about the focus or content of the training (eg. 
counselling, clinical care, HBC etc), and how long the training was for? 
Probe: Counseling skills, any training related to ART delivery, or did you get 
readings about it. 
2.2 How long was each of these training courses? 
2.3 How much discussion or input was given on adherence specifically? 
(Probe: how many training sessions/days focused on this issue; what key issues 
related to adherence did they focus on; or if not received – how did they access 
information on adherence?) 
3. ART and adherence to treatment 
3.1 What is the proportion of patients that are considered to be adherent to ART at 
this facility?   
3.2 What do you use to determine adherence in this facility? (Probe: appointments, 
irregular attendance at the hospital, refills?  
3.3 In your opinion and based on your experience what assists someone to be 
adherent? What are the characteristics of a patient or the characteristics of their 
circumstances that helps them be adherent?    
Probes: the support they have around them, whether they have disclosed or not, 
education, Knowledge of ART and the belief system in the value of the ARVs? 
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3.4 Similarly, what do you believe prevents patients from taking ART regularly?  Are 
there characteristics in a patient – or associated with their context - that leads to 
them to be non-adherent? 
Probes: costs to patients, lack of food, distance to the health facility, side effects, 
not having a treatment supporter, use of alcohol, fear of stigma and 
discrimination, feeling well? 
3.5 Currently what type of strategies or support are you offering ARV patients to 
keep them adherent to their drugs?  
Probes: Adherence counseling, ART outreach, community involvement etc 
3.6  From your experience what do you think are the particular challenges working in 
a rural area for keeping people on adherent on ART the particular challenges were 
working in a rural area for keeping folk adherent to ARTs? 
3.7 What do you think you need to do more of so as to support adherence to ARTs in 
this facility.  In other words, what do you think you need to do more of so as to 
increase the level of adherence - and the number of patients that are adherent? 
3.8 What specifically do you think you need to do or put in place to support non-   
adherent patients? 
3.9 What support would you need as a health worker to provide the additional type of 
adherence-related support or interventions for patients that you have just shared 
with me? 
 
I would like to thank you for taking time to answer to my questions. As I had mentioned 
at the beginning of the interview, I would like to re-assure you again that whatever we 
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have discussed here will be solely for the purpose of fulfilling my studies and help 
develop strategies that can support adherence in the rural areas. The information provided 
will be treated with strict confidence and your name will be not included in the report or 
other interviews. 
 
Is there anything else you would like to tell me or ask me? If not, thank you again for 
participating in this interview and wishing you the best. 
 
End of the interview 
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APPENDIX F: Guide to conducting focus group discussion with PLHIV 
support group members 
 
Introduction 
Greetings (Good morning or afternoon), My name is Charity Sisya and I am a student of 
Public Health with the University of Western Cape, In South Africa. Thanks for giving 
me this opportunity to meet with you all. I am interested in asking you a few questions, 
which are part of my student research, but will also assist me to identify the possible 
barriers and facilitators that could affect the level of ART adherence among people living 
with HIV/AIDS in rural communities. This hopefully will be used to support 
development of strategies that can support ART adherence in rural areas. To help me 
explain in detail, please here is the information sheet that we can read together and I can 
answer any questions that you might have. 
Note: Refer to the participant information sheet, read it in the local language for 
those that cannot read. Give an opportunity for questions.  
I just want to re-emphasize that refusal or with withdrawal from this process will not 
affect you in anyway – and particularly not in terms of the quality of the care or the 
support that you receive from the ART clinic.  
Once it established that each person in the group has no further questions, then ask 
the following 
I would like to know if you are willing to participate in this focus group discussion 
(FGD)?  
If the potential participant says NO: Thank you very much for taking the time to 
listen to me, I wish you the best.  
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If the potential participant has agreed to be part of the FGD, then proceed with the 
following: 
Thank you again for accepting to be part of the FGD.  This FGD will take only about 1 
hour to 2 hours. But before we start the FGD, I would like us to go through the informed 
consent form (refer to the consent form and use appropriate language),  
Note: emphasize the following  
• the interview process, 
• The participate can with draw at any stage or chose not to answer any questions 
that makes them uncomfortable 
• Issues of confidentiality,  
• why a tape recorder will be used during the process.  
Ensure that each participant signs the consent form, or consent is given on tape 
Before we begin the FGD, can we reach a consensus on the group rules for the FGD. As a 
group what would you like us to have as ground rules? 
As a group we also need to ensure that what is discussed here remains here.  
Thank you again, I just want to assure you all that everything discussed here will be used 
solely for the purpose of my studies and the findings will be reported back to the St Luke 
Mission Hospital. Your names will neither be included in the research report nor referred 
to during the interview process. 
 
1.  Knowledge and perceptions about ART 
1.1       What do you know about ARVs? 
1.2       How should the ARVs be taken, for example how often should the medicines be    
taken and for how long? 
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2 ART and adherence 
2.1     When people start ARV treatment, what stops them from continuing it or taking 
doses as prescribed?  
Probe: too expensive, time consuming, stigma and discrimination, denial of their 
status, lack of food, lack of employment, use of traditional medicines, being away 
from home, use of alcohol, distance from the facility, side effects, clinic waiting 
times being too long and others. 
2.2     From your experience, what do you think can help or helps people on ART remain 
adherent?  
Probes: knowledge of the ARVs medicines, disclosure, having social support, 
belief in the treatment, feeling well or better and others 
2.3    What support is given by the health workers to help people on ART to better adhere 
to their medication? 
2.4    What can be done by the PLHIV, support groups, family members, health workers 
and the community to support people on ART to remain adherent? 
2.5      What type of support do you think support groups or caregivers need for them to 
be most helpful for people taking ARVs to help them stick to their treatment? 
I would like to thank you all for taking time to answer to my questions. As I had 
mentioned at the beginning of the interview, I would like to re-assure you again that 
whatever we have discussed here will be solely for the purpose of fulfilling my studies 
and help develop strategies that can support ART adherence in the rural areas. The 
information provided will be treated with strict confidence and your name will be not 
included in the report or other interviews. 
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Is there anything else you would like to tell me or ask me? If not thank you to all you all 
for participating in the FGDs 
Note: if issues of further referral have been identified during the FGD then refer 
participant to the relevant support structures within the health facility. 
End of Focus Group Discussion
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APPENDIX G: Guide to conducting focus group discussion with 
caregivers (ART treatment
12
 supporters) 
 
Introduction 
Greetings (Good morning or afternoon), My name is Charity Sisya and I am a student of 
Public Health with the University of Western Cape, In South Africa. Thanks for giving 
me this opportunity to meet with you. I am interested in asking you a few questions, 
which are part of my student research, but will also assist me to identify the possible 
barriers and facilitators that could affect the level of ART adherence among people living 
with HIV/AIDS in rural communities. This hopefully will be used to support 
development of strategies that can support ART adherence in rural areas. To help me 
explain in detail, please here is the information sheet that we can read together and I can 
answer any questions that you might have. 
 
Note: Refer to the participant information sheet, read it in the local language for 
those that cannot read. Give an opportunity for questions.  
I just want to re-emphasize that refusal or with withdrawal from this process will not 
affect you in anyway – and particularly not in terms of the support that you receive from 
the ART clinic.  
Once it established that the person has no further questions, then ask the following 
Having read, I would like to know if you are willing to participate in this Focus group 
discussion (FGD)?  
 
                                                 
12 The questionnaire was adapted from the International HIV/AIDS Alliance study of the experiences of 
treatment users and health care workers, 2004 and WHO research From access to adherence: the 
challenges of antiretroviral treatment, studies from Bostwana, Tanzania and Uganda, July 2006. 
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If the potential participant says NO: Thank you very much for taking the time to 
listen to me, I wish you the best.  
If the potential participant has agreed to be part of the FGD, then proceed with the 
following: 
 
Thank you again for accepting to be part of the FGD.  This FGD will take only about 1 
hour to 2 hours. But before we start the interview, I would like us to go through the 
informed consent form (refer to the consent form and read in appropriate language),  
Note: Emphasize the following   
• the interview process, 
• The participate can with draw at any stage or chose not to answer any questions 
that makes them uncomfortable 
• Issues of confidentiality,  
• why a tape recorder will be used during the process.  
Ensure that each participant signs the consent form, or consent is given on tape  
Thank you again, I just want to assure you all that everything discussed here will be used 
solely for the purpose of my studies and the findings will be reported back to the St Luke 
Mission Hospital. Your names will neither be included in the research report nor referred 
to during the interview process. 
1.  Back ground information 
1.1. What is your role as caregivers or treatment supporters? 
1.2  How many PLWHIV do you support as a care provider? 
2.  Training 
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2.1. Have you undergone training to support you in being a caregiver or treatment 
supporter? Probes: Type of training such as Home Based Care skills, Treatment 
supporter, Counseling skills and others 
2.2. How long was the training?  
3.  ART adherence issues 
3.1.  From your experience as a caregiver or treatment support what keeps 
patients from taking ART regularly? 
Probes: age socioeconomic status, lack of Information (knowledge), beliefs, 
depression, distance to the facility, disruption of daily activities stigma and 
discrimination. 
3.2.     In your view, what do you think helps patients take their medicines as 
instructed? 
3.3.    What is currently in place at the facility and in the community to help people 
on     ART to adhere to their medication? 
Probes: Family, HBC support, support groups 
3.4. What do you think should be done or put in place at the facility to support 
PLHIV to adhere to ARVs? 
 
I would like to thank you all for taking time to answer to my questions. As I had 
mentioned at the beginning of the interview, I would like to re-assure you again that 
whatever we have discussed here will be solely for the purpose of fulfilling my studies 
and help develop strategies that can support ART adherence in the rural areas. The 
information provided will be treated with strict confidence and your names will be not 
included in the report or other interviews. 
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Is there anything else you would like to tell me or ask me? If not, then thank you again 
and wishing the best in your work 
End of the FGD 
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APPENDIX H: Participant Information Sheet for Individual Interviews 
 
 
 
 
 
 
 
 
 
               UNIVERSITY OF THE WESTERN CAPE 
SCHOOL OF PUBLIC HEALTH 
Private Bag X17 ? BELLVILLE ? 7535 ? South Africa 
               Tel: 021- 959 2809, Fax: 021- 959 2872 
 
 
October 2008 
 
Dear Participant 
 
Introduction 
 
Thank you very much for providing me with an opportunity to explain to you in detail 
about the research. I am Charity Sisya, a student at the SOPH, University of the Western 
Cape. As part of my Masters in Public Health I will be conducting a research to enable 
me complete my Masters degree.  
 
Purpose of the Research 
The purpose of the research is to identify possible barriers and facilitators that could 
affect the level of ART adherence among people living with HIV/AIDS (PLHIV). The 
findings of this research will contribute to understanding barriers and facilitators among 
PLHIV in rural areas and therefore assist the health facilities to develop strategies that 
can support ART adherence  
 
Interview process 
As part of the data collection process I would like to request that you participate in an 
individual interview. The individual interview will take about 1 to 2 hours.  A tape 
recorder will be used during this exercise. You are free to withdraw at any stage of the 
interview or discussion. You are free not to answer any questions that you are 
uncomfortable with you. Please note that refusal or with withdrawal from this process 
will not affect you in anyway. 
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Confidentiality 
The information you provide during this process will be kept confidential. You will be 
referred to with codes such as a number or letters and your name will not be disclosed. 
Issues around confidentiality will be discussed before you sign the consent form or give 
verbal consent.  Information collected both on tape and written down will be locked away 
at all times. All information collected will be destroyed as soon as the final research 
report is written up. 
 
Benefits and Costs
13
 
You will not receive any direct benefit from participating in this study, but you will 
receive a transport reimbursement of K10, 000. Your participation in this research will 
benefit others in providing understanding of the barriers and facilitators to adherence and 
therefore contribute to improving support for people on treatment in rural areas.  
 
Informed Consent 
Your verbal consent or signed consent is required before you take part in the interview. I 
will read the consent form with you and answer any of the questions you have. 
 
Questions 
For any questions, or if you need additional information, you can contact me on: 
 
Charity Sisya 
Cell phone: 097 7 474739 
Email address: charity.sisya@vsoint.org 
Telephone at work 260-1- 224469 
 
I am accountable to Ms. Nikki Schaay, my supervisor at UWC. Her contact details are as 
follows: 
Phone (South Africa) 084 211 5544/021-788 4186 
 
Email at schaay@mweb.co.za 
 
 
 
                                                 
13 This section of the information sheet will be adapted for health workers – who will not 
be paid any reimbursement for their participation in the study.  
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APPENDIX I: Participant Information Sheet for Focus Group 
Discussions 
 
 
 
 
 
 
 
 
 
               UNIVERSITY OF THE WESTERN CAPE 
SCHOOL OF PUBLIC HEALTH 
Private Bag X17 ? BELLVILLE ? 7535 ? South Africa 
               Tel: 021- 959 2809, Fax: 021- 959 2872 
 
 
October 2008 
 
Dear Participant 
 
Introduction 
 
Thank you very much for providing me with an opportunity to explain to you in detail 
about the research. I am Charity Sisya, a student at the SOPH, University of the Western 
Cape. As part of my Masters in Public Health I will be conducting a research to enable 
me complete my Masters degree.  
 
Purpose of the Research 
The purpose of the research is to identify possible barriers and facilitators that could 
affect the level of ART adherence among people living with HIV/AIDS (PLHIV). The 
findings of this research will contribute to understanding barriers and facilitators among 
PLHIV in rural areas and therefore assist the health facilities to develop strategies that 
can support ART adherence  
 
Interview process 
As part of the data collection process I would like to request that you participate in a 
focus group discussion (FGD). The FGD will take about 1 to 2 hours.  A tape recorder 
will be used during this exercise. You are free to withdraw at any stage of the interview 
or discussion. You are free not to answer any questions that you are uncomfortable with 
you. Please note that refusal or with withdrawal from this process will not affect you in 
anyway. 
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Confidentiality 
The information you provide during this process will be kept confidential. You will be 
referred to with codes such as a number or a letters and your name will not be disclosed. 
Issues around confidentiality will be discussed before you sign the consent form or give 
verbal consent.  Information collected both on tape and written down will be locked away 
at all times. All information collected will be destroyed as soon as the final research 
report is written up. 
 
Benefits and Costs 
You will not receive any direct benefit from participating in this study, but you will 
receive a transport reimbursement of K10, 000 and some snacks during the research 
process. Your participation in this research will benefit others in providing understanding 
of the barriers and facilitators to adherence and therefore contribute to improving support 
for people on treatment in rural areas.   
 
Informed Consent 
Your verbal consent or signed consent is required before you take part in the interview. I 
will read the consent form with you and answer any of the questions you have. 
 
Questions 
For any questions, or if you need additional information, you can contact me on: 
 
Charity Sisya 
Cell phone : 097 7 474739 
Emial address: charity.sisya@vsoint.org 
Telephone at work 260-1- 224469 
 
I am accountable to Ms. Nikki Schaay, my supervisor at UWC. Her contact details are as 
follows: 
Phone (South Africa) 084 211 5544/021-788 4186 
 
Email at schaay@mweb.co.za 
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APPENDIX J: Informed Consent 
 
 
 
 
 
 
 
 
 
UNIVERSITY OF THE WESTERN CAPE 
               School of Public Health 
 
Private Bag X17 ? BELLVILLE ? 7535 ? South Africa 
               Tel: 021- 959 2809, Fax: 021- 959 2872 
 
 
Thank you for agreeing to allow me to interview you. What follows is an explanation of 
the purpose and process of this interview. You are asked to give your consent to me on 
tape or in written form when we meet to conduct the interview. 
 
Information about the Interviewer 
I am Charity Sisya a student at the SOPH, University of the Western Cape. As apart of 
my Masters in Public Health, I am required to conduct a research. I will be focusing on 
adherence issues among ART users. I am accountable to Ms Nikki Schaay who can be 
contacted on schaay@mweb.co.za, or by calling (South Africa) 084 211 5544/021-788 
4186 
 
Purpose of interview 
To learn about some of the experiences people living with HIV/AIDS have in being 
adherent to ART. 
 
Interview process 
As part of the data collection exercise you are being requested to be a participant in a 
focus group discussion or an individual interview. The interview process will take 
between 1 to 2 hours.  A tape recorder will be used during this exercise. You are free to 
withdraw at any stage of the interview or discussion and you may chose not to answer 
any questions that make you uncomfortable. Please note that refusal or with withdrawal 
from this process will not affect you in anyway – and particularly not in terms of the 
quality of the care or the support that you receive from the ART clinic. 
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Confidentiality 
The information that you discuss with me during this process will be kept confidential. 
You will be referred to with codes such as numbers and letters when I write up my report. 
All information collected from these interviews will be destroyed after the research is 
completed. 
 
AGREEMENT 
I have read /or the information about this research has been read and explained to me.  
 
I have understood the purpose and I have had an opportunity to ask the questions and my 
questions have been answered.  
 
I voluntarily chose to participate in this research and I consent to be interviewed. 
 
 
Interviewee 
code………………………………………………………………………… 
 
 
Participant Name 
(printed)……………………………………………………………… 
 
  
Participant Signature & Date 
…………………………………………………………… 
 
 
Name of Researcher conducting the interview & obtaining informed 
consent……… 
………………………………………………………………………………………
…….. 
 
 
Researcher signature……………………………………………………………. 
(To accommodate those participants that might not be able to write, this signature will 
also certify that verbally consent has been given by the interviewee)   
 
Date 
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APPENDIX K: Ethics Committee approval letters 
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Figure 2: Ethics Committee approval letter, Department of Research Development—University of 
the Western Cape 
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Figure 3: Ethics Committee ???????? letter, Biomedical Research Ethics Committee—University of 
Zambia 
 
 
 
 
 
